



Family Planning and Pregnancy Issues for Women with Systemic Inflammatory Diseases: Patient and Physician Perspectives

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-004081
Article Type:	Research
Date Submitted by the Author:	25-Sep-2013
Complete List of Authors:	Chakravarty, Eliza; Oklahoma Medical Research Foundation, Arthritis & Clinical Immunology Research Program, MS 50 Clowse, Megan; Duke University Medical Center, Pushparajah, Daphnee; UCB Pharma, Mertens, Sarah; UCB Pharma, Gordon, Caroline; Birmingham University Medical School, Rheumatology Research Group
Primary Subject Heading:	Immunology (including allergy)
Secondary Subject Heading:	Rheumatology, Gastroenterology and hepatology, General practice / Family practice, Obstetrics and gynaecology, Patient-centred medicine
Keywords:	Pregnancy, Autoimmune disease, Inflammatory disease, Family Planning, Maternal medicine < OBSTETRICS

SCHOLARONE™
Manuscripts

Only

1
2
3 **Family Planning and Pregnancy Issues for Women with Systemic Inflammatory**
4 **Diseases: Patient and Physician Perspectives**
5
6
7
8

9 Eliza Chakravarty,¹ Megan E.B. Clowse,² Daphnee S. Pushparajah,³ Sarah Mertens,³ Caroline
10 Gordon⁴
11
12

13
14
15
16 ¹Oklahoma Medical Research Foundation, Oklahoma City, USA

17
18 ²Duke University Medical Center, Durham, USA

19
20 ³UCB Pharma, Brussels, Belgium

21
22 ⁴School of Immunity and Infection, College of Medical and Dental Sciences, University of
23 Birmingham, Birmingham, UK
24
25
26
27

28
29 **Correspondence to:**

Dr Eliza Chakravarty
Arthritis & Clinical Immunology Research Program, MS 50
Oklahoma Medical Research Foundation
825 N.E. 13th Street
Oklahoma City
OK 73104
USA
Telephone: +1 (405) 271-6042
Fax: +1 (405) 271-2319
Email: Eliza-Chakravarty@omrf.org

30
31
32
33
34
35
36
37
38
39
40
41
42 **Key Words**

43
44
45 Autoimmune Disease, Inflammatory Disease, Pregnancy, Family Planning
46
47
48

49 **Word Count:** 4,139
50
51
52

53
54 **Funding Statement**

55
56 This work was supported by UCB Pharma
57
58
59
60

Competing Interests Statement

EC has previously been reimbursed by UCB Pharma for consultation services; MEBC has previously been reimbursed by UCB Pharma for consultation services; DSP is an employee of UCB Pharma; SM is an employee of UCB Pharma; CG declared no competing interests.

Author Contributions

EC: substantial contribution to conception and design, interpretation of data, drafting and critical revision of the manuscript, and final approval of the manuscript for submission.

MEBC: substantial contribution to conception and design, interpretation of data, drafting and critical revision of the manuscript, and final approval of the manuscript for submission.

DSP: substantial contribution to conception and design, interpretation of data, drafting and critical revision of the manuscript, and final approval of the manuscript for submission.

SM: substantial contribution to conception and design, acquisition, analysis and interpretation of data, critical revision of the manuscript, and final approval of the manuscript for submission.

CG: substantial contribution to conception and design, interpretation of data, drafting and critical revision of the manuscript, and final approval of the manuscript for submission.

Abstract

Objectives: To identify family planning and pregnancy (FPP) issues for female patients of child-bearing age living with a chronic inflammatory disease and to assess whether current clinical practice routinely provides adequate support to alleviate these concerns.

Setting: Multinational survey and an analysis of online patient activity.

Participants: Premenopausal women (aged 20-45 years of age; N=969) were surveyed in USA, UK, Germany, France, Italy and Spain. Rheumatologists were surveyed in Germany (N=50), France (N=50), Italy (N=50) and the USA (N=100) and gastroenterologists were also surveyed in the USA (N=100).

Primary and Secondary Outcome Measures: Two online surveys were undertaken to identify FPP issues for both physicians and patients. The surveys examined the frequency of dialogue on these topics between physicians and patients, alongside assessment of patient satisfaction regarding these conversations. Online analysis identified key themes for patient discussion outside their doctors' office/clinic/surgery.

Results: 32-56% of physicians spontaneously reported having talked about FPP with their female patients of child-bearing age. When prompted, the majority of rheumatologists (74-92%) and gastroenterologists (74%) reported having discussed conception/pregnancy with female patients; however, less than half reported consulting their patient's treating GP/gynaecologist about these topics.

1
2
3 The majority of patients reported their FPP-related concerns are not adequately
4
5 addressed/settled during their medical appointments. Furthermore, only 30-40% of patients
6
7 considered advice/information to be consistent across multiple healthcare professionals.
8
9

10
11 Key online FPP-related patient discussions included: disease state, adverse effects,
12
13 treatment, switch behaviour and wash-out requirements.
14
15

16
17
18 **Conclusions:** Female patients who live with chronic inflammatory disease have important
19
20 FPP concerns. The majority of patients, however, do not feel that their FPP concerns are
21
22 adequately addressed in current clinical practice and report that they receive inconsistent
23
24 advice from the various healthcare professionals who manage different aspects of their care.
25
26 There is a clear need for provision of up-to-date and consistent information/support to
27
28 female patients.
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Article Summary

Article Focus:

- To identify key family planning and pregnancy (FPP) issues for female patients of child-bearing age who live with a chronic inflammatory disease and to assess whether current clinical practice routinely provides adequate support to alleviate these concerns.

Key Messages:

- Female patients of child-bearing years wish to discuss FPP issues in relation to their disease with their physicians but the majority of female patients who live with chronic inflammatory disease feel that their concerns are not adequately addressed.
- Physicians should initiate discussion of FPP issues with their female patients, particularly those receiving immunosuppressive treatment up to the ages of 50, and establish their expectations and concerns.
- Treating physicians should work to maintain this dialogue, at least once per year or when treatment changes, and align the advice offered to their female patients of child-bearing age with that from other physicians involved in their care.

Strengths and Limitations:

- Strengths: investigation of both patient and physician perspectives, involvement of specialists from different areas of interest and cross-cultural investigation.
- Limitations: absence of formal survey validation, reliance upon patient self-reporting, complications associated with delivery of the survey in local languages and possible bias in netnography research due to regional differences in language usage.

Introduction

Autoimmune and inflammatory diseases often affect women of reproductive age. Although RA becomes more common as patients age,¹ women are increasingly choosing to start their family later in life and treatments to control RA are now often started at a younger age. Moreover, even though only a minority proportion of RA patients are women of child-bearing age,² the high prevalence of the disease means that it does impact a significant number of young women. Many other inflammatory diseases, including ankylosing spondylitis (AS),^{3 4} Crohn's disease (CD),^{5 6} inflammatory bowel disease (IBD)⁷ and systemic lupus erythematosus (SLE),⁸ also affect a younger population and thus have a direct effect on women of child-bearing age.

Pregnancy and child rearing are important facets of life for most women. Now that improved therapies for inflammatory diseases have enabled better physical function and quality of life, many women who previously would have felt too ill to consider child-bearing are now better able to fulfil desires for family life. Family planning and pregnancy (FPP) are also important issues for this patient population as multiple studies have linked these disease states to a decreased chance of conceiving,⁹ carrying to full term¹⁰ and increasing the risk of other potential complications.¹¹⁻¹³ Due to this impact on pregnancy outcomes, expert advice is to achieve and maintain stable low disease activity prior to conception and throughout pregnancy.¹⁴⁻¹⁶ Some anti-inflammatory treatment options can be potentially hazardous for pregnant women to take as drugs can pass across the placenta and may affect the foetus.¹⁷ Methotrexate, a common RA treatment, can be damaging to foetal development (at least at high doses)^{18 19} whilst other disease-modifying anti-rheumatic drugs such as leflunomide have been shown to cause malformations in animal studies.²⁰

1
2
3 However, use of medications during pregnancy is not always contraindicated and an
4 individual risk-benefit discussion should be undertaken between the patient and expert
5 physician to provide the best management of both the disease and the pregnancy.²¹
6
7

8
9 Inadequate dissemination of appropriate advice describing which drugs may be continued
10 can lead to women unnecessarily forgoing potentially helpful medications and thus suffering
11 throughout pregnancy, with the increased risk of further complications to both mother and
12 child due to the effects of active disease.²² Furthermore, patients are increasingly seeking
13 additional information on the internet,²³ while a recent analysis of information regarding
14 medication safety on active internet sites has noted an inadequate evidence base for the
15 advice often provided and inconsistent guidance.²⁴ It is clear that communication of reliable
16 and consistent information is required to enable the correct treatment of these women
17 before and during pregnancy, and while breast-feeding. Education and information should
18 be shared by healthcare professionals dealing with these diseases, medications and
19 situations on a daily basis. Accurate, consistent information must be communicated to
20 women considering or entering pregnancy in order to support patients through this delicate
21 journey.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38

39 Two surveys were undertaken to investigate some of these issues, one of physicians and
40 another of female patients, to identify the key concerns of both groups related to the topics
41 of FPP in inflammatory disease. The surveys were designed to gauge whether there is a gap
42 in the communication between what healthcare professionals provide in terms of
43 information/support and what patients feel that they receive. The patient survey also
44 investigated where patients go to seek additional information. Two key objectives of the
45 study were to examine the proportion of physicians who discuss FPP issues with their female
46 patients of child-bearing age and the proportion of patients who have discussed these
47 topics, in the context of their condition, with their healthcare professional. The survey also
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 assessed the proportion of patients who feel that their concerns on this topic have been
4 satisfactorily addressed by these discussions. Here we aim to communicate the insights
5 gained from this investigation to clinicians treating women of child-bearing age, who live
6 with chronic inflammatory conditions, in order to provide advice on how best to support
7 these patients.
8
9
10
11
12

13 **Methods**

14 *Physician Survey*

15
16 The online physician questionnaire was delivered in two phases, the first phase (baseline)
17 was distributed in July 2012 (Europe) and September 2012 (USA), and the second phase
18 was distributed in November 2012 in both Europe and USA. The survey was delivered in the
19 local language and translations were checked for consistency against the original in English
20 by native speakers with fluency in both languages (the complete Physician Questionnaire
21 can be found online in Appendix 1). The questionnaire was designed to elicit both
22 spontaneous (open-ended question) and prompted (closed question in which FPP topics
23 were an option among other answering categories) responses. Participants were recruited
24 from the WorldOne Physician Panel. Rheumatologists were surveyed in four countries:
25 Germany (N=50), France (N=50), Italy (N=50) and the USA (N=100). Gastroenterologists
26 were surveyed in the USA (N=100). Responses were compared between phases using two-
27 sided z-tests with significance level 0.05, which corresponds to a confidence interval of 95%.
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

48 Participating physicians had to meet the following criteria: 3 to 30 years of experience,
49 ≥50% patient-facing time, had not participated in medical research within their specialist
50 area in the past month, were not currently a clinical investigator for a pharmaceutical
51 manufacturer and were not currently active in medical research or advertising. Physicians
52 with Rheumatology as their primary specialty had to meet the following additional criteria:
53
54
55
56
57
58
59
60

1
2
3 treat ≥ 20 RA patients per month and have ≥ 10 patients on biologics per month. Physicians
4
5 with Gastroenterology as their primary specialty had to meet the following additional
6
7 criteria: treat ≥ 8 CD patients per month and have ≥ 2 patients on biologics per month.
8
9

10 11 *Patient Survey*

12
13 The online patient questionnaire was designed according to standard market research
14
15 survey methodology, including scaling questions and avoiding skewed questions. The
16
17 questionnaire was delivered in the local language and translations were checked for
18
19 consistency against the original in English by native speakers with fluency in both languages
20
21 (the complete Patient Questionnaire can be found online in Appendix 2). The questionnaire
22
23 was targeted at premenopausal women (age was self-declared and the survey excluded
24
25 women under 20 and over 45 years of age; see Question 3 Patient Survey). A professional
26
27 recruitment agency was used to recruit patients.
28
29

30
31
32 The patient questionnaire was delivered in two phases and was distributed in six countries
33
34 (USA, UK, Germany, France, Italy and Spain). The first phase (baseline) consisted of 16
35
36 questions and was disseminated to patients between 17th July and 15th August 2012. There
37
38 were 1,069 respondents to the first phase which covered patients with RA, SLE, CD and
39
40 ulcerative colitis (UC). The second phase consisted of the original 16 questions from the first
41
42 phase plus an additional 8 questions included in order to avoid so-called 'false positives' (i.e.
43
44 covered topics included in other questions to test consistency of response) and to provide
45
46 greater insight into patients' experience in terms of medical care and needs. The second
47
48 phase elicited 969 responses and was distributed between 13th October and 16th November
49
50 2012 to patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA), in addition
51
52 to RA, SLE, CD and UC patients. All responses were anonymous. The patients who were
53
54 invited to participate in the two survey phases were not identical, although there may have
55
56
57
58
59
60

1
2
3 been some overlap (responses were anonymous therefore the extent of overlap could not be
4
5 determined).

6 7 8 9 *Netnography Research*

10
11 Online discussions (English language only) relating to FPP issues were investigated using
12
13 two approaches: social media monitoring, and search engine landscape/content analysis
14
15 (SELA).
16

17
18
19
20 Social media monitoring was undertaken by identifying categories of interest (defined as:
21
22 'ulcerative colitis', 'systemic lupus erythematosus', 'rheumatoid arthritis', 'colitis ulcerosa',
23
24 'lupus', 'regional enteritis', 'Crohn's disease') and keywords of interest (defined as:
25
26 'pregnancy', 'miscarriage', 'birth control', 'miscarriages', 'fertile', 'family planning', 'gestation',
27
28 'pregnant', 'fertility', 'pregnancy disease evolution', 'disease transfer to baby', 'breastfeeding',
29
30 'breast feeding', 'conception', 'conceived' and 'placental transfer'), and then combining
31
32 keywords together with the categories of interest to ensure coverage of all topics of interest.
33
34

35
36
37 SELA methodology involved identification of keywords (including generic keywords/keyword
38
39 phrases and specific keywords/keyword phrases), assessment of keyword search volume
40
41 and ranking of individual sites in search engine results. The 'click through rate' was
42
43 combined with the 'monthly search volume' to estimate the 'share of attention index'. The
44
45 final keyword pool included the categories 'colitis ulcerosa', 'ulcerative colitis', 'Crohn's
46
47 disease', 'lupus', 'rheumatoid arthritis', 'regional enteritis' and 'systemic lupus
48
49 erythematosus', and the following FPP-related keywords 'gestation', 'birth control',
50
51 'pregnancy', 'fertility', 'miscarriage' and 'family planning'.
52
53
54
55
56
57
58
59
60

Results

Physician Survey

Many rheumatologists and gastroenterologists spontaneously reported having discussed FPP-related topics with their female patients of child-bearing age; reports were consistent across all countries studied (Figure 1A). Interestingly, the number of US gastroenterologists who discussed these topics with their female patients increased significantly between the first and second Phases of the survey (Figure 1A). This was particularly true for fertility, pregnancy and/or family planning issues specifically, in which the percentage of US gastroenterologists discussing these topics increased from 67% to 79% between the two Phases (significant difference, 95% confidence level; N=100 for both survey phases); however there was no difference in European practice, with levels remaining at 60%.

When prompted, the majority of rheumatologists (74-92%) and gastroenterologists (74%) reported having discussed conception/pregnancy with female patients of child-bearing age. However, less than half of these physicians discussed FPP related issues with their patient's treating GP (i.e. primary care physician) or gynaecologist (Figure 1B and Figure 1C; survey Phase 2 data shown; see Questions 20 and 21 Physician Survey Appendix 1).

When seeking additional information regarding FPP, community rheumatologists and gastroenterologists reported currently relying on presentations and educational events at congresses, other healthcare professionals and key opinion leaders as their preferred sources of information.

Patient Survey and Netnography Analysis

Patients reported that the frequency of FPP-related conversations during their medical appointments was lower than their discussions about emotional well-being and employment (Figure 2A), although most female patients of child-bearing age (up to 85%) reported discussing these issues at some point during their care pathway (Figure 2B).

Patients currently on medication for the treatment of their condition reported being more concerned about FPP issues than those not receiving medication, with 63% of those on medication reporting that pregnancy was a concern compared to only 32% of patients not receiving medication. In addition, the female age group with most concerns related to FPP was between the ages of 30 and 34, with >60% of these patients reporting concerns (Figure 2C; survey Phase 2 data shown, similar trend observed in Phase 1). Concern was high between the ages of 25 and 39 (57-63%) but decreased to 44% in patients aged between 40 and 45.

Patients were asked when they would prefer to discuss the topics of FPP. The survey revealed that approximately 35% of patients prefer to discuss these issues in the context of their disease and treatment whenever a decision is made that could have an impact on their family planning or ability to become pregnant (Figure 3A). Approximately a quarter feel that one conversation with their healthcare professional on this topic is enough, although approximately 17% would like to discuss these topics at every visit. Furthermore, approximately a third of patients prefer to initiate conversations on this topic themselves (30-40% patients) or to obtain information from their healthcare professional when appropriate to their individual situation (15-35% patients).

1
2
3 Patients gave a range of reasons for not discussing FPP concerns with their healthcare
4 provider, with the most common reason being that they forgot to mention it (Figure 3B).
5
6 Other important reasons identified as barriers for discussing FPP was the impression that the
7 healthcare professional either did not have time for discussions or that they were not the
8 correct physician to provide advice on these topics. Importantly, some patients also reported
9 that they choose to not discuss FPP issues as they were reluctant to change medication.
10
11 Very few patients felt that their healthcare professional was reluctant to discuss these
12 topics. Over a quarter of respondents indicated that they had 'other' reasons for not
13 discussing these issues with their doctor (Figure 3B). A higher proportion (39%) of patients
14 aged 40-45 years recorded 'other' reasons for not discussing FPP issues with their doctor,
15 compared to younger patients ('other' was recorded by 21.7% of 20-24 year olds, 18.3% of
16 25-29 year olds, 18.7% of 30-34 year olds and 25.6% 35-39 year olds).
17
18
19
20
21
22
23
24
25
26
27
28
29
30

31 Patients report a preference for seeking information regarding FPP from their gynaecologist
32 (Figure 4A), whereas disease specialists (e.g. rheumatologist or gastroenterologist) are their
33 key contact point for management of their chronic condition (Figure 4B). GPs/primary care
34 physicians were also identified by patients as central to their discussions of both FPP and
35 their chronic condition (Figure 4A-B). It should be noted, however, that patient reports of a
36 preference for one specialist over another regarding FPP discussions could be expected to
37 vary by country given differences in treatment practices. For example, in the USA patients
38 may commonly visit a gynaecologist/obstetrician for all pregnancy care whereas in the UK
39 the patient's GP and local midwife may oversee most of their pregnancy planning and
40 management. In addition, when responding to the survey some, but not all, patients may
41 have regarded the terms 'obstetrician' and 'gynaecologist' as interchangeable based on their
42 own experience.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Other than their doctors' office/clinic/surgery, patients reported researching and discussing
4 information regarding FPP through multiple channels (Figure 4C): predominantly on disease-
5 related websites and with family and friends. In addition, patients reported that specific
6 condition-related forums/patient organisations did not play a prominent part in their search
7 for online information on these topics. A number of key themes, such as discussions around
8 disease state, adverse effects, treatment, switch behaviour and wash-out requirements,
9 emerged after following online patient activity. Other themes noted were patient emotions
10 and feelings, interactions with healthcare professionals, how best to identify the correct
11 healthcare professional for their treatment, concerns about inconsistent advice, infertility,
12 sexuality and conception, disease carry-over to the baby, placental transfer of treatments
13 and breastfeeding.
14
15
16
17
18
19
20
21
22
23
24
25
26
27

28
29 Importantly, approximately 30-55% of female patients reported that their concerns relating
30 to FPP are not adequately addressed or settled during their medical appointments (data
31 from patient survey Phase 2). Some variability in this response was observed across
32 countries, with 30% of patients from the USA, 34% from Italy, 35% from Spain, 39% from
33 the UK, 43% from France and 54% from Germany reporting their concerns were not settled
34 (data from patient survey Phase 2). Patients also reported that consistency of advice and
35 information given by multiple healthcare professionals, including nurses, was low with only
36 about 30-40% of patients reporting consistent advice. Again, responses to this question
37 varied across countries with 33% of patients reporting consistent advice from Spain and the
38 UK, 36% from Germany and Italy, 40% from the USA and 41% from France (data from
39 patient survey Phase 2). Inconsistent advice was reported by about 30-50% of patients
40 overall: 27% from Italy, 32% from Spain, 38% from France, 41% from the USA, 44% from
41 Germany and 49% from the UK (remaining patients selected a neutral response to this
42 question; data from patient survey Phase 2).
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Discussion

The investigation described here was carried out to illuminate some of the issues surrounding FPP for female patients of child-bearing age who live with chronic inflammatory diseases. Recently it was reported that almost half of female IBD patients feel their disease and/or treatment influences their decisions about FPP but despite this about two thirds had not discussed these issues with their doctor.²⁵ The results from the current study confirmed that FPP are considered important issues by this group of female patients and that there are key gaps in communication which result in inconsistent advice and subsequent patient concern/confusion. Importantly, the majority of female patients of child-bearing age reported that current clinical practice does not adequately address their concerns related to FPP in inflammatory disease.

Some clinical recommendations for the management of inflammatory disease during pregnancy have been published^{14-16 21 26} and advise that clinical remission/stable low disease activity be achieved prior to conception and maintained throughout pregnancy using appropriate therapy as needed. However, in the current study few patients reported discussing FPP at the point their condition was stable enough to become pregnant, suggesting a gap in necessary communication from physicians to patients regarding the need to control disease activity prior to conception, the impact of disease activity on pregnancy outcomes and the need to adjust medications during pregnancy. Indeed, a general lack of patient knowledge regarding continued use of medication during pregnancy was highlighted recently by a survey of female IBD patients which revealed a widespread, but inaccurate, belief that all medications needed to be stopped during pregnancy.²⁵ Respondents to the current patient survey also reported that inconsistencies in advice regarding the use of anti-inflammatory and immunosuppressive medications during

1
2
3 pregnancy are common. Together, these results suggest a need for continuing education of
4 all specialists involved in the care of women with inflammatory disease in order to ensure
5 women understand the implications of their condition and treatment on FPP. Timely
6 discussion of FPP issues is also an important consideration given a high percentage of
7 pregnancies are unplanned.²⁷ Congress presentations and associated education events were
8 identified by physicians, specifically rheumatologists and gastroenterologists, as their
9 currently preferred source of information and continuing education – which may also be
10 applicable to other specialists. As such, these events should be actively targeted to maximise
11 and improve continued education.
12
13
14
15
16
17
18
19
20
21
22
23

24 GPs/primary care physicians and gynaecologists were identified by patients as frequently
25 central to their discussions on FPP issues, although research has previously shown that 41%
26 of GPs do not initiate discussion of FPP with female patients affected by IBD.²⁵ Importantly a
27 gap in communication was identified between these physicians and the specialists who treat
28 chronic inflammatory diseases. As such, improved cross-specialty communication should be
29 strongly encouraged, particularly for discussions regarding planning and treatment
30 guidelines. A recent survey of GPs in Ireland did show that the majority of GPs report
31 seeking additional advice on FPP issues, in relation to their female IBD patients, from
32 tertiary specialists²⁵ so improved education for all specialties and fostering communication
33 should assist dissemination of information and consistent advice for patients. Furthermore,
34 all of those involved in the care of female patients of child-bearing age who live with chronic
35 inflammatory disease, not only the immunological disease specialists, should be exposed to
36 continued education on this topic.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53

54 In order to improve the dissemination of information regarding FPP to patients, it is
55 important to identify when patients prefer to receive such information and also why this
56
57
58
59
60

1
2
3 information may not be adequately communicated. Patient preference regarding timing of
4
5 discussions about FPP varied. This variability may be due to the personal nature of this
6
7 topic, differences in retention of information and differences in healthcare services/societal
8
9 norms across different countries. Patients did, however, generally report that they wished to
10
11 discuss FPP-related issues with their specialist physician (i.e. rheumatologist or
12
13 gastroenterologist) every time a decision was made that could impact upon their FPP. As
14
15 such, healthcare professionals should routinely consider any issues that affect fertility or
16
17 pregnancy and offer to have a conversation with their patient regarding these issues at
18
19 every clinic visit, unless it is known not to be relevant. It may also be useful to clarify patient
20
21 expectations for support and advice during these discussions. Patients on medication were
22
23 more concerned about FPP issues than those not receiving medication, as were female
24
25 patients between the ages of approximately 25 and 40. The high level of concern in both of
26
27 these groups highlights these patients as key populations requiring additional consideration,
28
29 although it could be argued that all women of child-bearing age should be targeted for such
30
31 communications.
32
33
34
35
36

37 The most common reason patients offered to explain why they did not raise FPP with their
38
39 healthcare provider was that they forgot to mention it during their consultation. Many also
40
41 stated they avoided such discussion as they did not want to change their medication,
42
43 implying that a fear of destabilising their disease could influence the preparedness of
44
45 patients to discuss FPP topics. Other key reasons identified were the impression that their
46
47 physician did not have time for the discussion or that they felt their treating physician was
48
49 not the correct physician to consult on these topics. Consequently, physicians should
50
51 consider periodically raising the issue themselves, particularly when treatment decisions or
52
53 disease activity could impact FPP plans. Notably over a quarter of respondents indicated that
54
55 they had 'other' reasons for not discussing these issues with their doctor. It is possible that
56
57
58
59
60

1
2
3 this high response was due to patient demographics (e.g. age, social background or current
4 use of contraception) and patients considering their family already complete. Indeed, a
5 higher proportion of older patients recorded 'other' reasons for not discussing FPP issues
6 with their doctor compared to younger patients. Patient emotions was an important theme
7 identified for online discussions, perhaps particularly relevant for those with a history of
8 miscarriage/stillbirth or infertility problems, and it should also be considered that such
9 associations could be a factor underlying why some patients reported that they did not
10 discuss FPP with their physician for 'other' reasons.
11
12
13
14
15
16
17
18
19
20
21

22 Of key importance, many female patients of child-bearing age reported that they did not feel
23 that their concerns relating to FPP in the context of their disease were adequately addressed
24 during their medical appointments. There was some variability in patient response across
25 countries to this question, suggesting that cultural differences and differences in healthcare
26 system structure may contribute to the variability in patient satisfaction. However, it is clear
27 that there can be a definite improvement in the response to these issues and all healthcare
28 professionals should consider how they could increase such communication and support to
29 their patients. This could include provision of better patient educational material and advice
30 on reliable and up-to-date websites containing FPP-related information. Indeed, patients
31 reported that they frequently sought information online, although specific condition-related
32 forums/patient organisations did not appear to be common sources of this information.
33 Furthermore, the online landscape was fragmented by disease area, with no specific
34 resource (beyond "Motherisk"; www.motherisk.org) that provides FPP guidance on common
35 autoimmune conditions and medication use affecting women in the reproductive age group.
36 As such, development of a single site with consistent up-to-date guidance covering topics
37 identified by patients as key interests would probably be of great value. Alternatively patient
38 and/or physician organisations could incorporate more detailed information and advice on
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 their websites to offer improved support to concerned patients and the various physicians
4 involved in their care during pregnancy. Another key improvement would be increased
5 dialogue, by telephone, letters or e-mail, between the varied physicians involved in an
6 individual patient's care in order to provide coordinated advice and support. Together these
7 measures would aim to improve patient support and satisfaction.
8
9
10
11
12

13
14
15 It should be noted that this study does have some limitations. Two important limitations of
16 the patient survey were an absence of formal survey validation and the reliance upon self-
17 reporting of diagnosis by patients. Furthermore, even though the surveys were translated
18 into local languages, differences in terminology and healthcare system structure exist across
19 countries which could impact pooling of results; for example, the terms obstetrician and
20 gynaecologist could be understood as being interchangeable in some countries but distinctly
21 different specialties in others meaning patient interpretation of the survey could vary. The
22 physician survey may also suffer related issues. In addition, the physician survey was only
23 delivered to gastroenterologists in the USA and did not investigate the activities of these
24 physicians in other countries. Furthermore, the netnography research may have been limited
25 by use of keywords common to one country/region but different in others (e.g. 'fertility' vs
26 'infertility') which could have restricted comprehensive analysis of the online landscape and
27 patient discussions. Finally, this study did not investigate the related concerns of men
28 suffering from inflammatory disease who may be using chronic medication and also
29 considering a family; indeed this population is often understudied and may need improved
30 support.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

50
51
52 In summary, FPP are extremely important issues for female patients of child-bearing age
53 who live with chronic inflammatory disease. A summary of key considerations, highlighted
54 by the results from the current study, for all physicians involved in the treatment of this
55
56
57
58
59
60

1
2
3 often neglected group of patients is presented in Figure 5. It is clear that female patients of
4
5 child-bearing age do wish to discuss these issues with their physicians although expectations
6
7 regarding frequency of discussion and their preferred physician for advice vary considerably.
8
9 Currently it appears that more can be done to provide these patients with consistent and co-
10
11 ordinated information regarding their disease and how it, and associated treatments, could
12
13 affect conception or pregnancy. Results from this study suggest physicians should regularly
14
15 initiate discussion of these topics with their female patients of child-bearing age, particularly
16
17 those on chronic medication or when changes to the treatment plan could impact pregnancy
18
19 outcome, in order to improve patient support. In addition, greater cross-speciality
20
21 communication between physicians involved in different aspects of the patient's care, from
22
23 gastroenterologists and rheumatologists to gynaecologists/obstetricians and GPs, is needed
24
25 to improve the consistency of advice offered to this often overlooked patient population.
26
27
28
29

30 **Acknowledgements**

31
32 This publication has been funded by UCB Pharma. The authors acknowledge InSites
33
34 Consulting and ACROSS HEALTH for survey development, management and analysis. The
35
36 authors also acknowledge Costello Medical Consulting for editorial and administrative
37
38 support.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Symmons D, Turner G, Webb R, Asten P, Barrett E, Lunt M, et al. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. *Rheumatology* 2002;41(7):793-800.
2. Symmons DP. Epidemiology of rheumatoid arthritis: determinants of onset, persistence and outcome. *Best practice & research. Clinical rheumatology* 2002;16(5):707-22.
3. Carbone LD, Cooper C, Michet CJ, Atkinson EJ, O'Fallon WM, Melton LJ, 3rd. Ankylosing spondylitis in Rochester, Minnesota, 1935-1989. Is the epidemiology changing? *Arthritis and rheumatism* 1992;35(12):1476-82.
4. J. SJaB. *Ankylosing Spondylitis in Clinical Practice*. Springer-Verlag London Limited, 2011.
5. Binder V. Epidemiology of IBD during the twentieth century: an integrated view. *Best practice & research. Clinical gastroenterology* 2004;18(3):463-79.
6. Gollop JH, Phillips SF, Melton LJ, 3rd, Zinsmeister AR. Epidemiologic aspects of Crohn's disease: a population based study in Olmsted County, Minnesota, 1943-1982. *Gut* 1988;29(1):49-56.
7. Loftus EV, Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. *Gastroenterology* 2004;126(6):1504-17.
8. Klippel JH. Systemic lupus erythematosus: demographics, prognosis, and outcome. *The Journal of rheumatology. Supplement* 1997;48:67-71.
9. Baird DD, Narendranathan M, Sandler RS. Increased risk of preterm birth for women with inflammatory bowel disease. *Gastroenterology* 1990;99(4):987-94.
10. van Dunne FM, Lard LR, Rook D, Helmerhorst FM, Huizinga TW. Miscarriage but not fecundity is associated with progression of joint destruction in rheumatoid arthritis. *Annals of the rheumatic diseases* 2004;63(8):956-60.
11. Morales M, Berney T, Jenny A, Morel P, Extermann P. Crohn's disease as a risk factor for the outcome of pregnancy. *Hepato-gastroenterology* 2000;47(36):1595-8.

- 1
2
3 12. Ostensen M. Sex hormones and pregnancy in rheumatoid arthritis and systemic lupus
4 erythematosus. *Annals of the New York Academy of Sciences* 1999;876:131-43;
5 discussion 44.
6
7
8
9
10 13. Bush MC, Patel S, Lapinski RH, Stone JL. Perinatal outcomes in inflammatory bowel
11 disease. *The journal of maternal-fetal & neonatal medicine : the official journal of the*
12 *European Association of Perinatal Medicine, the Federation of Asia and Oceania*
13 *Perinatal Societies, the International Society of Perinatal Obstet* 2004;15(4):237-41.
14
15
16
17
18 14. Mahadevan U, Cucchiara S, Hyams JS, Steinwurz F, Nuti F, Travis SP, et al. The London
19 Position Statement of the World Congress of Gastroenterology on Biological Therapy
20 for IBD with the European Crohn's and Colitis Organisation: pregnancy and
21 pediatrics. *The American journal of gastroenterology* 2011;106(2):214-23; quiz 24.
22
23
24
25
26
27 15. Ng SW, Mahadevan U. Management of inflammatory bowel disease in pregnancy. *Expert*
28 *review of clinical immunology* 2013;9(2):161-74.
29
30
31 16. Ostensen M, Forger F. Management of RA medications in pregnant patients. *Nature*
32 *reviews. Rheumatology* 2009;5(7):382-90.
33
34
35 17. Syme MR, Paxton JW, Keelan JA. Drug transfer and metabolism by the human placenta.
36 *Clinical pharmacokinetics* 2004;43(8):487-514.
37
38
39 18. Buckley LM, Bullaboy CA, Leichtman L, Marquez M. Multiple congenital anomalies
40 associated with weekly low-dose methotrexate treatment of the mother. *Arthritis and*
41 *rheumatism* 1997;40(5):971-3.
42
43
44
45
46 19. Lloyd ME, Carr M, McElhatton P, Hall GM, Hughes RA. The effects of methotrexate on
47 pregnancy, fertility and lactation. *QJM : monthly journal of the Association of*
48 *Physicians* 1999;92(10):551-63.
49
50
51
52 20. Brent RL. Teratogen update: reproductive risks of leflunomide (Arava); a pyrimidine
53 synthesis inhibitor: counseling women taking leflunomide before or during pregnancy
54
55
56
57
58
59
60

- 1
2
3 and men taking leflunomide who are contemplating fathering a child. *Teratology*
4
5 2001;63(2):106-12.
6
7 21. Chakravarty EF, Sanchez-Yamamoto D, Bush TM. The use of disease modifying
8
9 antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a
10
11 survey of practice patterns and pregnancy outcomes. *The Journal of rheumatology*
12
13 2003;30(2):241-6.
14
15 22. Langen ES, Chakravarty EF, Liaquat M, El-Sayed YY, Druzin ML. High Rate of Preterm
16
17 Birth in Pregnancies Complicated by Rheumatoid Arthritis. *American journal of*
18
19 *perinatology* 2013.
20
21 23. Hameen-Anttila K, Jyrkka J, Enlund H, Nordeng H, Lupattelli A, Kokki E. Medicines
22
23 information needs during pregnancy: a multinational comparison. *BMJ open*
24
25 2013;3(4).
26
27 24. Peters SL, Lind JN, Humphrey JR, Friedman JM, Honein MA, Tassinari MS, et al. Safe
28
29 lists for medications in pregnancy: inadequate evidence base and inconsistent
30
31 guidance from Web-based information, 2011. *Pharmacoepidemiology and drug*
32
33 *safety* 2013;22(3):324-8.
34
35 25. Toomey D, Waldron B. Family planning and inflammatory bowel disease: the patient and
36
37 the practitioner. *Family practice* 2013;30(1):64-8.
38
39 26. van der Woude CJ, Kolacek S, Dotan I, Oresland T, Vermeire S, Munkholm P, et al.
40
41 European evidenced-based consensus on reproduction in inflammatory bowel
42
43 disease. *Journal of Crohn's & colitis* 2010;4(5):493-510.
44
45 27. Finer LB, Henshaw SK. Disparities in rates of unintended pregnancy in the United States,
46
47 1994 and 2001. *Perspectives on sexual and reproductive health* 2006;38(2):90-6.
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Figure 1.** Frequency of physician-initiated discussions regarding FPP issues with female
4 patients and their GPs or gynaecologists (survey Phase 2 data shown in B and C)

5
6
7 *Abbreviations:* Ga = gastroenterologist; Rh = rheumatologist. * $p < 0.05$ compared to Phase 1
8
9 (two-sided z-test with significance level 0.05)
10


11
12
13 **Figure 2.** Patient reported (patient survey) topics of discussion with specialist physicians,
14 the frequency of patient-initiated FPP discussion and the importance of FPP issues stratified
15 by patient age (data from survey Phase 2 shown in C)
16
17

18
19
20
21
22 **Figure 3.** Patient preference for frequency of discussions relating to FPP issues and
23 identification of issues that prevented discussion (data from patient survey Phase 2 shown)
24
25


26
27
28 **Figure 4.** Patient preference for choice of healthcare provider for discussions of their
29 condition and FPP issues, and their preferred source of additional information (outside
30 doctors' office/clinic/surgery) relating to both their condition and FPP issues (data from
31 patient survey Phase 2 shown)
32
33
34
35

36
37
38 **Figure 5.** FPP-related considerations for practicing physicians treating female patients of
39 child-bearing age who live with chronic inflammatory disease: key messages from the survey
40 of current clinical practice and patient perceptions.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

A) Proportion of physicians who report having discussed family planning topics with female patients of child-bearing age (last 3 patients were considered)



B) Proportion of physicians who report having discussed family planning topics with a pregnant patient's GP



C) Proportion of physicians who report having discussed family planning topics with a pregnant patient's gynaecologist






Figure 1. Frequency of physician-initiated discussions regarding FPP issues with female patients and their GPs or gynaecologists (survey Phase 2 data shown in B and C). Abbreviations: Ga = gastroenterologist; Rh = rheumatologist. * $p < 0.05$ compared to Phase 1 (two-sided z-test with significance level 0.05).
180x253mm (300 x 300 DPI)

A) Topics discussed during any of the last three medical appointments



B) Have family planning concerns ever been discussed?



C) Are family planning issues of concern?





Figure 2. Patient reported (patient survey) topics of discussion with specialist physicians, the frequency of patient-initiated FPP discussion and the importance of FPP issues stratified by patient age (data from survey Phase 2 shown in C).
180x128mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

A) How often would you like the topic of family planning to be brought up during your medical appointments?



B) Issues that prevented a discussion




Figure 3. Patient preference for frequency of discussions relating to FPP issues and identification of issues that prevented discussion (data from patient survey Phase 2 shown).
180x126mm (300 x 300 DPI)

View only




Figure 4. Patient preference for choice of healthcare provider for discussions of their condition and FPP issues, and their preferred source of additional information (outside doctors' office/clinic/surgery) relating to both their condition and FPP issues (data from patient survey Phase 2 shown).
180x138mm (300 x 300 DPI)




Figure 5. FPP-related considerations for practicing physicians treating female patients of child-bearing age who live with chronic inflammatory disease: key messages from the survey of current clinical practice and patient perceptions.
145x117mm (300 x 300 DPI)

Appendix 1

Physician Survey Questionnaire

Overview – survey flow

1. Participant profiling and screening
2. Implicit measurement of impact FPP
3. Communication testing
4. Explicit measurement of FPP related conversations

Thank you for your interest in our study. Before we begin, we would like to assure you that we act in accordance with the ESOMAR, EphMRA, ABPI, MRS and BHBIA codes of conduct regarding anonymity and confidentiality.

Any information you disclose will be treated in the strictest confidence and the results are pooled so none of the answers are attributable to individual respondents.

First we would like to ask you a few qualifying questions. This will take less than 1 minute. The questionnaire takes some 20 minutes to complete and covers the domain of Rheumatoid Arthritis/Crohn's Disease.

The market research is being conducted on behalf of a pharmaceutical company. The market research study itself is strictly non-promotional. The company commissioning this research has no access whatsoever to information regarding respondents.

If you have any problems or questions filling out this questionnaire, please feel free to contact us at support@leadphysician.com.

- I hereby agree to proceed with the questionnaire on this basis. **STOP if not selected**

The participant should agree to treat with the utmost confidentiality all data and information to which he is made privy in light of and/or as a result of his participation in this study.

The participant expressly guarantees that he will not divulge said information or data, nor will third parties be granted access. He will not publish or reproduce the information, nor will he exploit it in any other way.

Only public information or information that the participant may also obtain via other legitimate means than through participation in this study are not subject to this obligation of confidentiality.

This obligation is irrevocable and remains in effect as long as the information is to be considered confidential and has, therefore, not been made public by the authorized party or parties.

- Yes, I expressly and unconditionally accept the above obligation of confidentiality.
STOP if not selected

ADVERSE EVENT REPORTING: We have been asked to provide our client with details of adverse events divulged during the course of this market research. Although this is an online survey and the information you provide will of course be treated in confidence, we are still under an obligation to report any information on adverse events in specific patients, even if you have already reported said event to the company or the regulatory authorities. In this case you will be contacted with a request to waive the confidentiality provided under the market research codes of conduct specifically for this particular adverse event. All other information you provide during the course of the survey will remain confidential.

- I hereby confirm to have been informed that the organiser of the survey is under the obligation to collect and report all information on adverse events linked to the client's product as recorded by me during the course of this research. **STOP if not selected**

[Parameters to be recorded from panel database:

- Age
- Gender
- Region
- No Clinical investigation or pharma/biotech manufacturer (not in US)]

PARTICIPANT PROFILING AND SCREENING

1. What is your primary specialty?

Question type: Single response

- | | |
|---|---------------------|
| <input type="checkbox"/> Gastroenterology (US only) | =GASTROENTEROLOGIST |
| <input type="checkbox"/> Rheumatology | = RHEUMATOLOGIST |
| <input type="checkbox"/> Internal medicine specialized in rheumatology (Germany only) | = RHEUMATOLOGIST |
| <input type="checkbox"/> Internal medicine not specialized in rheumatology (Germany only) | STOP |
| <input type="checkbox"/> Other specialty | STOP |

[Gastroenterologists get questions personalized to Crohn's Disease, Rheumatologists to Rheumatoid Arthritis.]

2. How long have you been IN PRACTICE since qualifying as a specialist?

[Question type: Open comment - numeric

Max score allowed: 50 ("Years" - next to box)]

[If < 3 or > 30 => STOP]

3. What percent of your working time is dedicated to treating patients?

1
2
3 [Question type: Open comment - numeric

4
5 0 to 100%]

6
7
8
9 % is dedicated to treating patients [STOP if less than 50%]

10
11
12
13
14
15 **4. In an average month, approximately how many different patients do you see for all disorders**
16 **and conditions and for whom you are personally involved in making treatment decisions? Please**
17 **count each patient once, not the number of visits.**

18
19 [Question type: Open comment - numeric

20
21 Max score allowed: 1000]

22
23 [STOP if <20]

24
25

26
27
28
29
30
31 **5. In an average month, approximately how many different patients do you see for Rheumatoid**
32 **Arthritis (for Rheumatologists)/ Crohn's Disease (for Gastroenterologists) and for whom you are**
33 **personally involved in making treatment decisions? Please count each patient once, not the**
34 **number of visits.**

35
36 [Question type: Open comment - numeric

37
38 Max score allowed: number at S4

39
40 Number needs to be lower or equal than in previous question.]

41
42 [STOP if < 20 RA patients or < 8 CD patients]

43
44

1
2
3 **6. In an average month, approximately how many different patients with Rheumatoid Arthritis**
4 **(for Rheumatologists)/ Crohn's Disease (for Gastroenterologists) do you see that are on biologic**
5 **treatment?**
6

7 *[Question type: Open comment - numeric]*

8
9 *Max score allowed: Number in S5*

10
11 *Number needs to be lower or equal than in previous question]*

12
13 *[STOP if < 10 RA patients or < 2 CD patients]*

14
15
16

17
18
19 **7. What type of practice do you have? (tick only one)**

20
21 *[Question type: Single response]*

- 22
23 Office only *[STOP in France]*
24 Hospital only
25 Office and hospital *[(don't show in Germany)]*
26
27

28
29 **8. What is the size of hospital where you carry out your regular practice?**

30
31 *[Question type: Single response]*

32
33 *[Show only if 'hospital' or 'office and hospital' was selected in q0]*

- 34 More than 700 beds
35 400 to 700 beds
36 Less than 400 beds
37

38
39 **9. Have you taken part in a market research study in the area of Rheumatoid Arthritis (for**
40 **Rheumatologists)/ Crohn's Disease (for Gastroenterologists) in the last month?**

41 *[Question type: Single response]*

- 42
43 Yes **[STOP]**
44 No
45

46
47 **10. What percentage of your Rheumatoid Arthritis/Crohn's Disease patient base can be attributed**
48 **to the following categories?**

49
50 *[Question type: Open comment - numeric]*

51
52 *Should add up to 100%*

53

Male younger than 45 years old	%
Male 45 years or older	%
Female younger than 45 years old	%
Female 45 years or older	%

54
55
56
57
58
59
60

IMPLICIT MEASUREMENT OF IMPACT FPP

In the following questions we would like to talk about the topics you discussed with your moderate to severe Rheumatoid Arthritis/Crohn's Disease patients.

Obviously, most of the conversations are about clinical topics, but from now on we would like you to think about **non clinical nor treatment related topics**.

11. Please think back about your last 6 [3: IF Q10_1 OR Q10_2=0] male patients with moderate to severe Rheumatoid Arthritis/Crohn's Disease that were initiated on treatment by you. Which topics did you discuss with these patients?

Please bear in mind to mention non clinical and non-treatment related topics.

[Question type: Open comment – text]

	Last 3 patients younger than 45 years old [only show if Q10 "Male younger than 45 years old" > 0]	Last 3 patients of 45 years or older [only show if Q10 "Male 45 years or older" > 0]
Male patient 1		
Male patient 2		
Male patient 3		

12. Please think back about your last 6 [3: IF Q10_3 OR Q10_4=0] female patients with moderate to severe Rheumatoid Arthritis/Crohn's Disease that were initiated on treatment by you. Which topics did you discuss with these patients?

Please bear in mind to mention non clinical and non-treatment related topics.

[Question type: Open comment – text]

	Last 3 patients younger than 45 years old [only show if Q10 "Female younger than 45 years old" > 0]	Last 3 patients of 45 years or older [only show if Q10 "Female 45 years or older" > 0]
Female patient 1		
Female patient 2		
Female patient 3		

1
2
3 **13. Please think back about your last male patients with moderate to severe Rheumatoid**
4 **Arthritis/Crohn's Disease that were initiated on treatment by you.**

5
6 **Other than disease related topics, which of the following topics did you discuss with these**
7 **patients?.**

8
9
10 *[Question type: Multiple response]*

11 *[Randomisation: Yes]*

12
13
14
15 LAST 3 MALE PATIENTS YOUNGER THAN 45 YEARS *[only show if Q10 "Male younger than 45 years*
16 *old" > 0]*

- 17
18 Ability to gain/maintain employment
19 Emotional wellbeing of the patient
20 Social life of the patient
21 Conception / having children
22 Sex life
23 Sports activities
24 Leisure / holiday
25 Independent living of the patient
26 Family life
27 Finances
28 Other (please specify)
29 None of the above

30
31 LAST 3 MALE PATIENTS OF 45 YEARS OR OLDER *[only show if Q10 "Male 45 years or older" > 0]*

- 32
33 Ability to gain/maintain employment
34 Emotional wellbeing of the patient
35 Social life of the patient
36 Conception / having children
37 Sex life
38 Sports activities
39 Leisure / holiday
40 Independent living of the patient
41 Family life
42 Finances
43 Other (please specify)
44 None of the above

45
46
47
48 **14. Below, we have listed the topics you discussed with your last male patients with moderate to**
49 **severe Rheumatoid Arthritis/Crohn's Disease.**

50
51
52 Please select the 5 topics you spent most time on, and rank them by attributing a score between 1
53 and 5, where 1 indicates the topic you spent most time on.

54
55 *[PN: Show text before each part of question and adjust number of topics selected when less than 5]*

56
57 *[Question type: ranking (top 5)]*
58
59
60

1
2
3 *Randomisation: Yes]*
4 *[Filter: only show options selected in Q13]*
5
6

7 LAST 3 MALE PATIENTS YOUNGER THAN 45 YEARS (max 5)
8

- 9 Ability to gain/maintain employment
- 10 Emotional wellbeing of the patient
- 11 Social life of the patient
- 12 Conception / having children
- 13 Sex life
- 14 Sports activities
- 15 Leisure / holiday
- 16 Independent living of the patient
- 17 Family life
- 18 Finances
- 19 Other (please specify)

20
21 LAST 3 MALE PATIENTS OF 45 YEARS OR OLDER (max 5)
22

- 23 Ability to gain/maintain employment
- 24 Emotional wellbeing of the patient
- 25 Social life of the patient
- 26 Conception / having children
- 27 Sex life
- 28 Sports activities
- 29 Leisure / holiday
- 30 Independent living of the patient
- 31 Family life
- 32 Finances
- 33 Other (please specify)

34
35
36 **15. Please think of your last male patient with whom you discussed conception / having children.**
37

38 **Who initiated this discussion on conception / having children?**
39

40 *[Question type: Single response]*
41

42 *[Filter: only show if "Conception / having children" is selected in Q0]*
43

- 44 I initiated this discussion
- 45 The patient initiated this discussion
- 46 I don't remember who initiated this discussion
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

1
2
3 **16. Please think back about your last female patients with moderate to severe Rheumatoid**
4 **Arthritis/Crohn's Disease that were initiated on treatment by you.**

5
6 **Other than disease related topics, which of the following topics did you discuss with these**
7 **patients?**

8
9
10 *[Question type: Multiple response]*

11 *[Randomisation: Yes]*

12
13
14
15 LAST 3 FEMALE PATIENTS YOUNGER THAN 45 YEARS *[only show if Q10 "Female younger than 45*
16 *years old" > 0]*

- 17
18 Ability to gain/maintain employment
19 Emotional wellbeing of the patient
20 Social life of the patient
21 Conception / having children
22 Sex life
23 Sports activities
24 Leisure / holiday
25 Independent living of the patient
26 Family life
27 Finances
28 Other (please specify)
29 None of the above

30
31 LAST 3 FEMALE PATIENTS OF 45 YEARS OR OLDER *[only show if Q10 "Female 45 years or older" > 0]*

- 32
33 Ability to gain/maintain employment
34 Emotional wellbeing of the patient
35 Social life of the patient
36 Conception / having children
37 Sex life
38 Sports activities
39 Leisure / holiday
40 Independent living of the patient
41 Family life
42 Finances
43 Other (please specify)
44 None of the above

45
46
47
48 **17. Below, we have listed the topics you discussed with your last female patients with moderate**
49 **to severe Rheumatoid Arthritis/Crohn's Disease.**

50
51
52 **Please select the 5 topics you spent most time on, and rank them by attributing a score between 1**
53 **and 5, where 1 indicates the topic you spent most time on.**

54
55 *[PN: Show text before each part of question and adjust number of topics selected when less than 5]*

56
57 *[Question type: ranking (top 5)]*

1
2
3 [Randomisation: Yes]

4 [Filter: only show options selected in Q16]

5
6
7 LAST 3 FEMALE PATIENTS YOUNGER THAN 45 YEARS (max 5)

- 8
9 Ability to gain/maintain employment
- 10 Emotional wellbeing of the patient
- 11 Social life of the patient
- 12 Conception / having children
- 13 Sex life
- 14 Sports activities
- 15 Leisure / holiday
- 16 Independent living of the patient
- 17 Family life
- 18 Finances
- 19 Other (please specify)

20
21 LAST 3 PATIENTS OF 45 YEARS OR OLDER (max 5)

- 22
23 Ability to gain/maintain employment
- 24 Emotional wellbeing of the patient
- 25 Social life of the patient
- 26 Conception / having children
- 27 Sex life
- 28 Sports activities
- 29 Leisure / holiday
- 30 Independent living of the patient
- 31 Family life
- 32 Finances
- 33 Other (please specify)

34
35 **18. Please think of your last female patient with whom you discussed conception / having**

36 **children.**

37
38 **Who initiated this discussion on conception / having children?**

39
40 [Question type: Single response]

41
42 [Filter: only show if "Conception / having children" is selected in Q6]

- 43
44 I initiated this discussion
- 45 The patient initiated this discussion
- 46 I don't remember who initiated this discussion
- 47
48
49
50
51
52
53
54
55
56
57
58
59
60

QUESTIONS REGARDING FPP MANAGEMENT

In the next chapter, we would like to ask you some questions regarding the Family Planning and Pregnancy management of your patients with moderate to severe Rheumatoid Arthritis/Crohn's Disease.

19. How often do you consult the following channel(s) in order to look for extra information regarding Family Planning and Pregnancy issues?

[Question type: Single response]

[Randomise options]

	Always	Very often	Sometimes	Rarely	Never
Congresses/meetings	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Medical Science Liaison (MSL)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Sales representative	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Industry-sponsored symposia or meetings	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Company websites with disease management education	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Social media (e.g. Facebook, LinkedIn, Twitter) for your profession (please specify):	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Other healthcare professionals (peers)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Expert opinion blogs (please specify):	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Physician communities (please specify):	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
KOLs (Key Opinion Leaders)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Online consultation	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Other (please specify):	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

The family planning and/or pregnancy related issues, questions... your patients with moderate to severe Rheumatoid Arthritis/Crohn's Disease could have, might also be relevant for their other treating physicians.

[Filter: only show if "Conception / having children" is selected in Q0 or Q0]

20. To what extent do you discuss these questions, issues... with the patient's GP?

[Question type: Single response]

[Filter: only show if "Conception / having children" is selected in Q0 or Q0]

1 Never discuss with patient's GP	2	3	4	5 Always discuss with patient's GP
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

21. To what extent do you discuss these questions, issues... with the patient's gynaecologist?

[Question type: Single response]

[Filter: only show if "Conception / having children" is selected in Q0]

1 Never discuss with patient's gynaecologist	2	3	4	5 Always discuss with patient's gynaecologist
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Appendix 2**Patient Survey Questionnaire**

1. Please specify the country where you live:

- United States
- United Kingdom
- France
- Italy
- Germany
- Spain
- Other (OUT)

2. Please specify your gender:

- Male (OUT)
- Female

3. Please specify your age:

- Under 20 years (OUT)
- 20-24 years
- 25-29 years
- 30-34 years
- 35-39 years
- 40-45 years
- Over 45 years (OUT)

1
2
3 4. How many children have you given birth to?
4
5

- 6 • None
- 7 • One
- 8 • Two
- 9 • Three
- 10 • Four
- 11 • Five or more

12
13
14
15
16
17
18 5. Do you have an immunological condition? If so, which one? (If you have more
19 than one of these conditions, tick the one that is most prominent)

- 20 • Rheumatoid arthritis
- 21 • Systemic lupus
- 22 • Crohn's disease
- 23 • Ulcerative colitis
- 24 • Axial spondyloarthritis
- 25 • Psoriatic arthritis
- 26 • None (OUT)
- 27 • Other (OUT)

28
29
30
31
32
33
34
35
36
37
38
39 6. Are you currently taking any medication for your condition?
40

- 41 • Yes
 - 42 • No
- 43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Next, we would like to ask you a few questions around your visits to your doctor.
4

5 7. Which doctor(s) did you visit during the last two years for your condition? (please
6
7 tick all that apply)

- 9 • GP
- 10
- 11 • Gynaecologist
- 12
- 13 • Rheumatologist
- 14
- 15 • Gastroenterologist
- 16
- 17 • Immunologist
- 18
- 19 • Dermatologist
- 20
- 21 • Other
- 22
- 23

24 8. During any of your last three medical appointments, did you discuss any of the
25
26 following topics in relation to your condition? (please tick all that apply)

- 27 • Employment
- 28
- 29 • Emotional wellbeing
- 30
- 31 • Social life
- 32
- 33 • Having children/pregnancy [if ticked, option 9 of Q11 was hidden]
- 34
- 35 • Sex life
- 36
- 37 • Sports activities
- 38
- 39 • Leisure/holiday
- 40
- 41 • Independent living
- 42
- 43 • Family life
- 44
- 45 • Finances
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

1
2
3 Finally, we would like to ask you about family planning (having children), and how you
4
5 discuss this during your medical appointment.
6

7 9. Are you considering having a child/another child?

- 8
9
10
11
12
- Yes
 - No

13
14 10. Do you consider your condition a point of concern for family planning (i.e. for
15 your plans of having another child)?

- 16
17
18
19
20
21
- Yes
 - No

22 11. Have you ever discussed your concerns around your condition and family
23 planning with a healthcare professional (specialist, GP or nurse)? (please tick all
24 that apply)
25
26
27

- 28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- Yes, with my GP
 - Yes, with my gynaecologist
 - Yes, with my paediatrician
 - Yes, with my rheumatologist
 - Yes, with my gastroenterologist
 - Yes, with my immunologist
 - Yes, with my dermatologist
 - Yes, with a nurse
 - No, I haven't discussed this [this option will not appear if FPP is ticked in Q8; if ticked only Q16-23 subsequently shown]
 - Other

1
2
3 12. When was the last time you discussed your concerns around your condition and
4
5 family planning with a healthcare professional (specialist, GP or nurse)?
6

- 7 • Less than six months ago
- 8
- 9 • Between six months and two years ago
- 10
- 11 • More than two years ago
- 12
- 13 • Don't remember
- 14

15
16 13. Over the last five years, how frequently did you have a discussion on your
17
18 concerns around your condition and family planning with a healthcare
19
20 professional (specialist, GP or nurse)?
21

- 22 • Every visit
- 23
- 24 • Most visits
- 25
- 26 • Occasionally, during some visits
- 27
- 28 • Just once
- 29
- 30 • Never
- 31
- 32 • Don't remember
- 33
- 34

35 14. Who initiated the last discussion around your condition and family planning?
36

- 37 • I did
- 38
- 39 • The doctor or nurse did
- 40
- 41 • Don't remember
- 42

43 15. To what extent did that discussion settle concerns? (please rate on a scale from
44
45 0 to 10 where 0 = no, the discussion didn't settle my concerns at all, and 10 =
46
47 yes, the discussion completely settle my concerns)
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 16. Do you intend to make family planning a discussion point during your next
4
5 medical appointment? (omitted in UK)
6

- 7
- 8 • Yes, definitely
 - 9 • Yes, probably
 - 10 • Maybe
 - 11 • No, probably not
 - 12 • No, definitely not
- 13
14
15
16
17

18 *Additional questions for Phase 2 questionnaire*
19

20 17. Which of the issues listed below prevented you from discussing your concerns
21
22 around your condition and family planning during your medical appointments?
23
24 (maximum 2)
25

- 26
- 27 • Not enough time on behalf of my doctor or other healthcare professional
 - 28 • I forgot to bring up my concerns
 - 29 • I feel the healthcare professionals I am seeing are unable to help me here
 - 30 • The healthcare professionals I am seeing are reluctant to enter into this
31 discussion
 - 32 • I am very worried that bringing up my concerns will trigger a change in
33 my medication, which will make symptoms worse
 - 34 • Other
- 35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 18. What type of healthcare professional (specialist, GP or nurse) are you primarily
4
5 seeing in relation to your condition? (only 1 allowed)
6

- 7 • GP
- 8
- 9 • Gynaecologist
- 10
- 11 • Paediatrician
- 12
- 13 • Rheumatologist
- 14
- 15 • Gastroenterologist
- 16
- 17 • Immunologist
- 18
- 19 • Dermatologist
- 20
- 21 • Nurse
- 22
- 23 • Other
- 24
- 25

26
27 19. What type of healthcare professional (specialist, GP or nurse) are you primarily
28
29 seeing in relation to family planning and pregnancy? (only 1 allowed)
30

- 31 • GP
- 32
- 33 • Gynaecologist
- 34
- 35 • Paediatrician
- 36
- 37 • Rheumatologist
- 38
- 39 • Gastroenterologist
- 40
- 41 • Immunologist
- 42
- 43 • Dermatologist
- 44
- 45 • Nurse
- 46
- 47 • Other
- 48
- 49

50 20. If you discussed your concerns around family planning and your condition with
51
52 several healthcare professionals (specialists, GP or nurse), how consistent would
53
54 you say the answers were? (please rate on a scale from 0 to 10 where 0 = the
55
56 answers were not consistent at all, and 10 = the answers were very consistent)
57
58
59
60

1
2
3 21. Which channels are you using to find information about family planning as
4
5 impacted by your condition? (please tick all that apply)
6

- 7 • Family and friends
- 8
- 9 • Fellow patients
- 10
- 11 • Other pregnant women and mothers
- 12
- 13 • Twitter
- 14
- 15 • Facebook
- 16
- 17 • Specific condition related websites
- 18
- 19 • Specific pregnancy related websites
- 20
- 21 • Health blogs
- 22
- 23 • Specific condition related forums (online)
- 24
- 25 • Specific pregnancy related forums (online)
- 26
- 27 • TV
- 28
- 29 • Magazines or e-magazines
- 30
- 31 • Books or e-books
- 32
- 33 • DVDs/CDs
- 34
- 35 • Patient organisations
- 36
- 37 • Radio
- 38
- 39 • Health and wellness clubs
- 40
- 41 • Religious groups
- 42
- 43 • Condition related groups (not online)
- 44
- 45 • Other
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

1
2
3 22. Which channels are you using to engage (comment, discuss, post, share, like) in
4 discussions around family planning as impacted by your condition? (please tick all
5 that apply)
6
7
8

- 9 • Family and friends
- 10 • Fellow patients
- 11 • Other pregnant women and mothers
- 12 • Twitter
- 13 • Facebook
- 14 • Specific condition related websites
- 15 • Specific pregnancy related websites
- 16 • Health blogs
- 17 • Specific condition related forums (online)
- 18 • Specific pregnancy related forums (online)
- 19 • Patient organisations
- 20 • Health and wellness clubs
- 21 • Religious groups
- 22 • Condition related groups (not online)
- 23 • Other

1
2
3 23. What is in your opinion the best way to bring up the topic of family planning and
4
5 your condition during a medical appointment?
6

- 7
- 8 • I would like a healthcare professional (specialist, GP or nurse) to initiate
9 the discussion
10
 - 11 • I would like a healthcare professional (specialist, GP or nurse) to provide
12 me with some informational materials about family planning and my
13 condition
14
 - 15 • I would prefer to initiate the discussion myself
16
 - 17 • I would prefer not to have such discussion [GO TO END]
18
 - 19 • Other [GO TO END]
20
21
22
23

24 24. How often would you like the topic of family planning be brought up during your
25
26 medical appointments?
27

- 28
- 29 • Once is enough
30
 - 31 • At every visit
32
 - 33 • When changing my medication
34
 - 35 • When taking decisions that could have an impact on my family planning
36
 - 37 • Regularly, at least once a year
38
 - 39 • Every time when my condition is stable enough to become pregnant
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Family Planning and Pregnancy Issues for Women with Systemic Inflammatory Diseases: Patient and Physician Perspectives

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-004081.R1
Article Type:	Research
Date Submitted by the Author:	18-Dec-2013
Complete List of Authors:	Chakravarty, Eliza; Oklahoma Medical Research Foundation, Arthritis & Clinical Immunology Research Program, MS 50 Clowse, Megan; Duke University Medical Center, Pushparajah, Daphnee; UCB Pharma, Mertens, Sarah; UCB Pharma, Gordon, Caroline; Birmingham University Medical School, Rheumatology Research Group
Primary Subject Heading:	Immunology (including allergy)
Secondary Subject Heading:	Rheumatology, Gastroenterology and hepatology, General practice / Family practice, Obstetrics and gynaecology, Patient-centred medicine
Keywords:	Pregnancy, Autoimmune disease, Inflammatory disease, Family Planning, Maternal medicine < OBSTETRICS

SCHOLARONE™
Manuscripts

Only

1
2
3 **Family Planning and Pregnancy Issues for Women with Systemic Inflammatory**
4
5 **Diseases: Patient and Physician Perspectives**
6
7

8
9 Eliza Chakravarty,¹ Megan E.B. Clowse,² Daphnee S. Pushparajah,³ Sarah Mertens,³ Caroline
10
11 Gordon⁴
12

13
14
15
16 ¹Oklahoma Medical Research Foundation, Oklahoma City, USA

17
18 ²Duke University Medical Center, Durham, USA

19
20 ³UCB Pharma, Brussels, Belgium

21
22 ⁴School of Immunity and InfecAtion, College of Medical and Dental Sciences, University of
23
24 Birmingham, Birmingham, UK
25
26

27
28
29 **Correspondence to:**

Dr Eliza Chakravarty
Arthritis & Clinical Immunology Research Program, MS 50
Oklahoma Medical Research Foundation
825 N.E. 13th Street
Oklahoma City
OK 73104
USA
Telephone: +1 (405) 271-6042
Fax: +1 (405) 271-2319
Email: Eliza-Chakravarty@omrf.org

30
31
32
33
34
35
36
37
38
39
40
41
42 **Key Words**

43
44
45 Autoimmune Disease, Inflammatory Disease, Pregnancy, Family Planning
46
47

48
49 **Word Count:** 4,139
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objectives: To identify family planning and pregnancy (FPP) issues for female patients of child-bearing age living with a chronic inflammatory disease and to assess whether current clinical practice routinely provides adequate support to alleviate these concerns.

Setting: Multinational survey and an analysis of online patient activity.

Participants: Premenopausal women (aged 20-45 years of age; N=969) were surveyed in USA, UK, Germany, France, Italy and Spain. Rheumatologists were surveyed in Germany (N=50), France (N=50), Italy (N=50) and the USA (N=100) and gastroenterologists were also surveyed in the USA (N=100).

Primary and Secondary Outcome Measures: Two online surveys were undertaken to identify FPP issues for both physicians and patients. The surveys examined the frequency of dialogue on these topics between physicians and patients, alongside assessment of patient satisfaction regarding these conversations. Online analysis identified key themes for patient discussion outside their doctors' office/clinic/surgery.

Results: 32-56% of physicians spontaneously reported having talked about FPP with their female patients of child-bearing age. When prompted, the majority of rheumatologists (74-92%) and gastroenterologists (74%) reported having discussed conception/pregnancy with female patients; however, less than half reported consulting their patient's treating GP/gynaecologist about these topics.

1
2
3 The majority of patients reported their FPP-related concerns are not adequately
4 addressed/settled during their medical appointments. Furthermore, only 30-40% of patients
5 considered advice/information to be consistent across multiple healthcare professionals.
6
7
8
9

10
11 Key online FPP-related patient discussions included: disease state, adverse effects,
12 treatment, switch behaviour and wash-out requirements.
13
14
15

16
17
18 **Conclusions:** Female patients who live with chronic inflammatory disease have important
19 FPP concerns. The majority of patients, however, do not feel that their FPP concerns are
20 adequately addressed in current clinical practice and report that they receive inconsistent
21 advice from the various healthcare professionals who manage different aspects of their care.
22
23
24
25
26
27 There is a clear need for provision of up-to-date and consistent information/support to
28 female patients.
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Article Summary

Article Focus:

- To identify key family planning and pregnancy (FPP) issues for female patients of child-bearing age who live with a chronic inflammatory disease and to assess whether current clinical practice routinely provides adequate support to alleviate these concerns.

Key Messages:

- Female patients of child-bearing years wish to discuss FPP issues in relation to their disease with their physicians but the majority of female patients who live with chronic inflammatory disease feel that their concerns are not adequately addressed.
- Physicians should initiate discussion of FPP issues with their female patients, particularly those receiving immunosuppressive treatment up to the ages of 50, and establish their expectations and concerns.
- Treating physicians should work to maintain this dialogue, at least once per year or when treatment changes, and align the advice offered to their female patients of child-bearing age with that from other physicians involved in their care.

Strengths and Limitations:

- Strengths: investigation of both patient and physician perspectives, involvement of specialists from different areas of interest and cross-cultural investigation.
- Limitations: absence of formal survey validation, reliance upon patient self-reporting, complications associated with delivery of the survey in local languages and possible bias in netnography research due to regional differences in language usage.

Introduction

Autoimmune and inflammatory diseases often affect women of reproductive age. Although RA becomes more common as patients age,¹ women are increasingly choosing to start their family later in life and treatments to control RA are now often started at a younger age. Moreover, even though only a minority proportion of RA patients are women of child-bearing age,² the high prevalence of the disease means that it does impact a significant number of young women. Many other inflammatory diseases, including ankylosing spondylitis (AS),^{3 4} Crohn's disease (CD),^{5 6} inflammatory bowel disease (IBD)⁷ and systemic lupus erythematosus (SLE),⁸ also affect a younger population and thus have a direct effect on women of child-bearing age.

Pregnancy and child rearing are important facets of life for most women. Now that improved therapies for inflammatory diseases have enabled better physical function and quality of life, many women who previously would have felt too ill to consider child-bearing are now better able to fulfil desires for family life. Family planning and pregnancy (FPP) are also important issues for this patient population as these disease states have been linked to an increased risk of adverse pregnancy outcomes,⁹⁻¹¹ including increased risk of preterm birth,¹² difficulty carrying to full term¹³ and a possible reduction in fertility,^{14 15} although there is conflicting evidence regarding the impact of inflammatory diseases on fertility.^{16 17} Due to the impact on pregnancy outcomes, expert advice is to achieve and maintain stable low disease activity prior to conception and throughout pregnancy.¹⁸⁻²⁰ Some anti-inflammatory treatment options can be potentially hazardous for pregnant women to take as drugs can pass across the placenta and may affect the foetus.²¹ Methotrexate, a common RA treatment, can be damaging to foetal development (at least at high doses)^{22 23} whilst other disease-modifying anti-rheumatic drugs such as leflunomide have been shown to cause malformations in animal studies.²⁴

1
2
3
4
5 However, use of medications during pregnancy is not always contraindicated and an
6
7 individual risk-benefit discussion should be undertaken between the patient and expert
8
9 physician to provide the best management of both the disease and the pregnancy.²⁵
10
11 Inadequate dissemination of appropriate advice describing which drugs may be continued
12
13 can lead to women unnecessarily forgoing potentially helpful medications and thus suffering
14
15 throughout pregnancy, with the increased risk of further complications to both mother and
16
17 child due to the effects of active disease.²⁶ Furthermore, patients are increasingly seeking
18
19 additional information on the internet,²⁷ while a recent analysis of information regarding
20
21 medication safety on active internet sites has noted an inadequate evidence base for the
22
23 advice often provided and inconsistent guidance.²⁸ It is clear that communication of reliable
24
25 and consistent information is required to enable the correct treatment of these women
26
27 before and during pregnancy, and while breast-feeding. Education and information should
28
29 be shared by healthcare professionals dealing with these diseases, medications and
30
31 situations on a daily basis. Accurate, consistent information must be communicated to
32
33 women considering or entering pregnancy in order to support patients through this delicate
34
35 journey.
36
37
38
39
40

41 Two surveys were undertaken to investigate some of these issues, one of physicians and
42
43 another of female patients, to identify the key concerns of both groups related to the topics
44
45 of FPP in inflammatory disease. The surveys were designed to gauge whether there is a gap
46
47 in the communication between what healthcare professionals provide in terms of
48
49 information/support and what patients feel that they receive. The patient survey also
50
51 investigated where patients go to seek additional information. Two key objectives of the
52
53 study were to examine the proportion of physicians who discuss FPP issues with their female
54
55 patients of child-bearing age and the proportion of patients who have discussed these
56
57
58
59
60

1
2
3 topics, in the context of their condition, with their healthcare professional. The survey also
4
5 assessed the proportion of patients who feel that their concerns on this topic have been
6
7 satisfactorily addressed by these discussions. Here we aim to communicate the insights
8
9 gained from this investigation to clinicians treating women of child-bearing age, who live
10
11 with chronic inflammatory conditions, in order to provide advice on how best to support
12
13 these patients.
14
15

16 17 18 **Methods**

19
20 This study complied with the ICC/ESOMAR, EphMRA, ABPI, MRS and BHBIA market research
21
22 codes of conduct, ensuring the anonymity and confidentiality of all participants.
23

24 Respondents were paid a nominal amount, calculated using fair market value guidance, to
25
26 compensate for the time and effort of completing the survey.
27
28

29 30 31 *Physician Survey*

32
33 The online physician questionnaire was delivered in two phases, the first phase (baseline)
34
35 was distributed in July 2012 (Europe) and September 2012 (USA), and the second phase
36
37 was distributed in November 2012 in both Europe and USA. The survey was delivered in the
38
39 local language and translations were checked for consistency against the original in English
40
41 by native speakers with fluency in both languages (the complete Physician Questionnaire
42
43 can be found online in Appendix 1). The questionnaire was designed to elicit both
44
45 spontaneous (open-ended question) and prompted (closed question in which FPP topics
46
47 were an option among other answering categories) responses. Participants were recruited
48
49 from the WorldOne Physician Panel. Rheumatologists were surveyed in four countries:
50
51 Germany (N=50), France (N=50), Italy (N=50) and the USA (N=100). Gastroenterologists
52
53 were surveyed in the USA (N=100). Responses were compared between phases using two-
54
55 sided z-tests with significance level 0.05, which corresponds to a confidence interval of 95%.
56
57
58
59
60

1
2
3
4
5 Participating physicians had to meet the following criteria: 3 to 30 years of experience,
6
7 $\geq 50\%$ patient-facing time, had not participated in medical research within their specialist
8
9 area in the past month, were not currently a clinical investigator for a pharmaceutical
10
11 manufacturer and were not currently active in medical research or advertising (to avoid
12
13 inclusion of respondents motivated only by receipt of payment). Physicians with
14
15 Rheumatology as their primary specialty had to meet the following additional criteria: treat
16
17 ≥ 20 RA patients per month and have ≥ 10 patients on biologics per month. Physicians with
18
19 Gastroenterology as their primary specialty had to meet the following additional criteria:
20
21 treat ≥ 8 CD patients per month and have ≥ 2 patients on biologics per month. These
22
23 selection criteria were applied to ensure participating physicians had sufficient experience
24
25 treating patients with systemic inflammatory disease in order to provide informative results,
26
27 while also seeking to include physicians with a range of experience in order to investigate
28
29 routine clinical practice.
30
31
32
33
34

35 *Patient Survey*

36
37 The online patient questionnaire was designed according to standard market research
38
39 survey methodology, including scaling questions and avoiding skewed questions. The
40
41 questionnaire was delivered in the local language and translations were checked for
42
43 consistency against the original in English by native speakers with fluency in both languages
44
45 (the complete Patient Questionnaire can be found online in Appendix 2). The questionnaire
46
47 was targeted at premenopausal women (age was self-declared and the survey excluded
48
49 women under 20 and over 45 years of age; see Question 3 Patient Survey). A professional
50
51 recruitment agency was used to recruit patients from the GlobalTestMarket and MySurvey
52
53 online survey panels. Respondents were screened according to age, gender and disease (all
54
55 self-reported) and those who were < 20 or > 45 years old, male, or not suffering from RA,
56
57
58
59
60

1
2
3 CD or lupus were excluded. Recruited patients were then sent a link to an online survey,
4
5 which was followed up by a short telephone interview at a pre-arranged time.
6
7

8
9 The patient questionnaire was delivered in two phases and was distributed in six countries
10 (USA, UK, Germany, France, Italy and Spain). The first phase (baseline) consisted of 16
11 questions and was disseminated to patients between 17th July and 15th August 2012. There
12 were 1,069 respondents to the first phase which covered patients with RA, SLE, CD and
13 ulcerative colitis (UC). The second phase consisted of the original 16 questions from the first
14 phase plus an additional 8 questions included in order to avoid so-called 'false positives' (i.e.
15 covered topics included in other questions to test consistency of response) and to provide
16 greater insight into patients' experience in terms of medical care and needs. The second
17 phase elicited 969 responses and was distributed between 13th October and 16th November
18 2012 to patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA), in addition
19 to RA, SLE, CD and UC patients. All responses were anonymous. The patients who were
20 invited to participate in the two survey phases were not identical, although there may have
21 been some overlap (responses were anonymous therefore the extent of overlap could not be
22 determined).
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40

41 *Netnography Research*

42 Online discussions (English language only) relating to FPP issues were investigated using
43 two approaches: social media monitoring, and search engine landscape/content analysis
44 (SELA).
45
46
47
48
49
50

51
52 Social media monitoring was undertaken by identifying categories of interest (defined as:
53 'ulcerative colitis', 'systemic lupus erythematosus', 'rheumatoid arthritis', 'colitis ulcerosa',
54 'lupus', 'regional enteritis', 'Crohn's disease') and keywords of interest (defined as:
55
56
57
58
59
60

1
2
3 'pregnancy', 'miscarriage', 'birth control', 'miscarriages', 'fertile', 'family planning', 'gestation',
4
5 'pregnant', 'fertility', 'pregnancy disease evolution', 'disease transfer to baby', 'breastfeeding',
6
7 'breast feeding', 'conception', 'conceived' and 'placental transfer'), and then combining
8
9 keywords together with the categories of interest to ensure coverage of all topics of interest.
10

11
12
13 SELA methodology involved identification of keywords (including generic keywords/keyword
14
15 phrases and specific keywords/keyword phrases), assessment of keyword search volume
16
17 and ranking of individual sites in search engine results. The 'click through rate' was
18
19 combined with the 'monthly search volume' to estimate the 'share of attention index'. The
20
21 final keyword pool included the categories 'colitis ulcerosa', 'ulcerative colitis', 'Crohn's
22
23 disease', 'lupus', 'rheumatoid arthritis', 'regional enteritis' and 'systemic lupus
24
25 erythematosus', and the following FPP-related keywords 'gestation', 'birth control',
26
27 'pregnancy', 'fertility', 'miscarriage' and 'family planning'.
28
29
30
31
32

33 **Results**

34 *Physician Survey*

35
36
37 Many rheumatologists and gastroenterologists spontaneously reported having discussed
38
39 FPP-related topics with their female patients of child-bearing age; reports were consistent
40
41 across all countries studied (Figure 1A). Interestingly, the number of US gastroenterologists
42
43 who discussed these topics with their female patients increased significantly between the
44
45 first and second Phases of the survey (Figure 1A). This was particularly true for fertility,
46
47 pregnancy and/or family planning issues specifically, in which the percentage of US
48
49 gastroenterologists discussing these topics increased from 67% to 79% between the two
50
51 Phases (significant difference, 95% confidence level; N=100 for both survey phases);
52
53 however there was no difference in European practice, with levels remaining at 60%.
54
55
56
57
58
59
60

1
2
3 When prompted, the majority of rheumatologists (74-92%) and gastroenterologists (74%)
4 reported having discussed conception/pregnancy with female patients of child-bearing age.
5
6 However, less than half of these physicians discussed FPP related issues with their patient's
7
8 treating GP (i.e. primary care physician) or gynaecologist (Figure 1B and Figure 1C; survey
9
10 Phase 2 data shown; see Questions 20 and 21 Physician Survey Appendix 1).
11
12
13

14
15
16 When seeking additional information regarding FPP, community rheumatologists and
17
18 gastroenterologists reported currently relying on presentations and educational events at
19
20 congresses, other healthcare professionals and key opinion leaders as their preferred
21
22 sources of information.
23
24

25 26 *Patient Survey and Netnography Analysis* 27

28
29 Patients reported that the frequency of FPP-related conversations during their medical
30
31 appointments was lower than their discussions about emotional well-being and employment
32
33 (Figure 2A), although most female patients of child-bearing age reported discussing these
34
35 issues at some point during their care pathway (Figure 2B).
36
37

38
39 Patients currently on medication for the treatment of their condition reported being more
40
41 concerned about FPP issues than those not receiving medication, with 63% of those on
42
43 medication reporting that pregnancy was a concern compared to only 32% of patients not
44
45 receiving medication. In addition, the female age group with most concerns related to FPP
46
47 was between the ages of 30 and 34 (Figure 2C; survey Phase 2 data shown, similar trend
48
49 observed in Phase 1). Concern was high between the ages of 25 and 39 but decreased in
50
51 patients aged between 40 and 45.
52
53
54
55
56
57
58
59
60

1
2
3 Patients were asked when they would prefer to discuss the topics of FPP. The survey
4 revealed patients prefer to discuss these issues in the context of their disease and treatment
5 whenever a decision is made that could have an impact on their family planning or ability to
6 become pregnant (Figure 3A). Approximately a quarter feel that one conversation with their
7 healthcare professional on this topic is enough, although some would like to discuss these
8 topics at every visit. Furthermore, approximately a third of patients prefer to initiate
9 conversations on this topic themselves or to obtain information from their healthcare
10 professional when appropriate to their individual situation.
11
12
13
14
15
16
17
18
19
20
21

22 Patients gave a range of reasons for not discussing FPP concerns with their healthcare
23 provider, with the most common reason being that they forgot to mention it (Figure 3B).
24 Other important reasons identified as barriers for discussing FPP was the impression that the
25 healthcare professional either did not have time for discussions or that they were not the
26 correct physician to provide advice on these topics. Importantly, some patients also reported
27 that they choose to not discuss FPP issues as they were reluctant to change medication.
28 Very few patients felt that their healthcare professional was reluctant to discuss these
29 topics. Over a quarter of respondents indicated that they had 'other' reasons for not
30 discussing these issues with their doctor (Figure 3B). A higher proportion (39%) of patients
31 aged 40-45 years recorded 'other' reasons for not discussing FPP issues with their doctor,
32 compared to younger patients ('other' was recorded by 21.7% of 20-24 year olds, 18.3% of
33 25-29 year olds, 18.7% of 30-34 year olds and 25.6% 35-39 year olds).
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

50 Patients report a preference for seeking information regarding FPP from their gynaecologist
51 (Figure 4A), whereas disease specialists (e.g. rheumatologist or gastroenterologist) are their
52 key contact point for management of their chronic condition (Figure 4B). GPs/primary care
53 physicians were also identified by patients as central to their discussions of both FPP and
54
55
56
57
58
59
60

1
2
3 their chronic condition (Figure 4A-B). It should be noted, however, that patient reports of a
4 preference for one specialist over another regarding FPP discussions could be expected to
5 vary by country given differences in treatment practices. For example, in the USA patients
6 may commonly visit a gynaecologist/obstetrician for all pregnancy care whereas in the UK
7 the patient's GP and local midwife may oversee most of their pregnancy planning and
8 management. In addition, when responding to the survey some, but not all, patients may
9 have regarded the terms 'obstetrician' and 'gynaecologist' as interchangeable based on their
10 own experience.
11
12
13
14
15
16
17
18
19
20
21

22 Other than their doctors' office/clinic/surgery, patients reported researching and discussing
23 information regarding FPP through multiple channels (Figure 4C): predominantly on disease-
24 related websites and with family and friends. In addition, patients reported that specific
25 condition-related forums/patient organisations did not play a prominent part in their search
26 for online information on these topics. A number of key themes, such as discussions around
27 disease state, adverse effects, treatment, switch behaviour and wash-out requirements,
28 emerged after following online patient activity. Other themes noted were patient emotions
29 and feelings, interactions with healthcare professionals, how best to identify the correct
30 healthcare professional for their treatment, concerns about inconsistent advice, infertility,
31 sexuality and conception, disease carry-over to the baby, placental transfer of treatments
32 and breastfeeding.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

48 Importantly, approximately 30-55% of female patients reported that their concerns relating
49 to FPP are not adequately addressed or settled during their medical appointments (data
50 from patient survey Phase 2). Some variability in this response was observed across
51 countries, with 30% of patients from the USA, 34% from Italy, 35% from Spain, 39% from
52 the UK, 43% from France and 54% from Germany reporting their concerns were not settled
53
54
55
56
57
58
59
60

1
2
3 (data from patient survey Phase 2). Patients also reported that consistency of advice and
4 information given by multiple healthcare professionals, including nurses, was low with only
5 about 30-40% of patients reporting consistent advice. Again, responses to this question
6 varied across countries with 33% of patients reporting consistent advice from Spain and the
7 UK, 36% from Germany and Italy, 40% from the USA and 41% from France (data from
8 patient survey Phase 2). Inconsistent advice was reported by about 30-50% of patients
9 overall: 27% from Italy, 32% from Spain, 38% from France, 41% from the USA, 44% from
10 Germany and 49% from the UK (remaining patients selected a neutral response to this
11 question; data from patient survey Phase 2).
12
13
14
15
16
17
18
19
20
21
22
23

24 Discussion

25
26 The investigation described here was carried out to illuminate some of the issues
27 surrounding FPP for female patients of child-bearing age who live with chronic inflammatory
28 diseases. Recently it was reported that almost half of female IBD patients feel their disease
29 and/or treatment influences their decisions about FPP but despite this about two thirds had
30 not discussed these issues with their doctor.²⁹ The results from the current study confirmed
31 that FPP are considered important issues by this group of female patients and that there are
32 key gaps in communication which result in inconsistent advice and subsequent patient
33 concern/confusion. Importantly, the majority of female patients of child-bearing age
34 reported that current clinical practice does not adequately address their concerns related to
35 FPP in inflammatory disease.
36
37
38
39
40
41
42
43
44
45
46
47
48
49

50 Some clinical recommendations for the management of inflammatory disease during
51 pregnancy have been published^{18-20 25 30} and advise that clinical remission/stable low disease
52 activity be achieved prior to conception and maintained throughout pregnancy using
53 appropriate therapy as needed. However, in the current study few patients reported
54
55
56
57
58
59
60

1
2
3 discussing FPP at the point their condition was stable enough to become pregnant,
4
5 suggesting a gap in necessary communication from physicians to patients regarding the
6
7 need to control disease activity prior to conception, the impact of disease activity on
8
9 pregnancy outcomes and the need to adjust medications during pregnancy. Indeed, a
10
11 general lack of patient knowledge regarding continued use of medication during pregnancy
12
13 was highlighted recently by a survey of female IBD patients which revealed a widespread,
14
15 but inaccurate, belief that all medications needed to be stopped during pregnancy.²⁹
16
17 Respondents to the current patient survey also reported that inconsistencies in advice
18
19 regarding the use of anti-inflammatory and immunosuppressive medications during
20
21 pregnancy are common. Together, these results suggest a need for continuing education of
22
23 all specialists involved in the care of women with inflammatory disease in order to ensure
24
25 women understand the implications of their condition and treatment on FPP. Congress
26
27 presentations and associated education events were identified by physicians, specifically
28
29 rheumatologists and gastroenterologists, as their currently preferred source of information
30
31 and continuing education – which may also be applicable to other specialists. As such, these
32
33 events should be actively targeted to maximise and improve continued education. This
34
35 could, for example, include hosting discussion forums between specialists involved in
36
37 different aspects of care for these patients at international and national congresses. Timely
38
39 discussion of FPP issues is also an important consideration given a high percentage of
40
41 pregnancies are unplanned.³¹
42
43
44
45
46
47

48 GPs/primary care physicians and gynaecologists were identified by patients as frequently
49
50 central to their discussions on FPP issues, although research has previously shown that 41%
51
52 of GPs do not initiate discussion of FPP with female patients affected by IBD.²⁹ Importantly a
53
54 gap in communication was identified between these physicians and the specialists who treat
55
56 chronic inflammatory diseases. As such, improved cross-specialty communication should be
57
58
59
60

1
2
3 strongly encouraged, particularly for discussions regarding planning and treatment
4
5 guidelines. This could involve establishment of cross-specialty teams within hospitals/centres
6
7 of excellence to co-ordinate care of pregnant women living with systemic inflammatory
8
9 disease. A recent survey of GPs in Ireland did show that the majority of GPs report seeking
10
11 additional advice on FPP issues, in relation to their female IBD patients, from tertiary
12
13 specialists²⁹ so improved education for all specialties and fostering communication should
14
15 assist dissemination of information and consistent advice for patients. Furthermore, all of
16
17 those involved in the care of female patients of child-bearing age who live with chronic
18
19 inflammatory disease, not only the immunological disease specialists, should be exposed to
20
21 continued education on this topic. Another recent survey of rheumatologists and
22
23 obstetricians showed that there is variability in advice given to patients concerning the use
24
25 of specific medication during pregnancy.³² This highlights a need for consistency amongst
26
27 clinicians to achieve quality patient care. Development of cross-specialty international
28
29 guidelines/consensus papers by relevant expert physicians may help bridge these gaps in
30
31 communication. Furthermore, publication of evidence-based discussions of the risks and
32
33 benefits of medication use and disease activity control during pregnancy in women with
34
35 inflammatory diseases by relevant medical societies could provide an easily accessible
36
37 resource for physicians and patients alike. These could be in the form of “white papers” and
38
39 accompanying patient information pieces, published in the scientific literature and online, to
40
41 provide consistent education and advice for cross-specialty physicians and their patients.
42
43
44
45
46
47

48 In order to improve the dissemination of information regarding FPP to patients, it is
49
50 important to identify when patients prefer to receive such information and also why this
51
52 information may not be adequately communicated. Patient preference regarding timing of
53
54 discussions about FPP varied. This variability may be due to the personal nature of this
55
56 topic, differences in retention of information and differences in healthcare services/societal
57
58
59
60

1
2
3 norms across different countries. Patients did, however, generally report that they wished to
4 discuss FPP-related issues with their specialist physician (i.e. rheumatologist or
5 gastroenterologist) every time a decision was made that could impact upon their FPP. As
6 such, healthcare professionals should routinely consider any issues that affect fertility or
7 pregnancy and offer to have a conversation with their patient regarding these issues at
8 every clinic visit, unless it is known not to be relevant. It may also be useful to clarify patient
9 expectations for support and advice during these discussions. Patients on medication were
10 more concerned about FPP issues than those not receiving medication, as were female
11 patients between the ages of approximately 25 and 40. The high level of concern in both of
12 these groups highlights these patients as key populations requiring additional consideration,
13 although it could be argued that all women of child-bearing age should be targeted for such
14 communications.

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31 The most common reason patients offered to explain why they did not raise FPP with their
32 healthcare provider was that they forgot to mention it during their consultation. Many also
33 stated they avoided such discussion as they did not want to change their medication,
34 implying that a fear of destabilising their disease could influence the preparedness of
35 patients to discuss FPP topics. Other key reasons identified were the impression that their
36 physician did not have time for the discussion or that they felt their treating physician was
37 not the correct physician to consult on these topics. Consequently, physicians should
38 consider periodically raising the issue themselves, particularly when treatment decisions or
39 disease activity could impact FPP plans. Notably over a quarter of respondents indicated that
40 they had 'other' reasons for not discussing these issues with their doctor. It is possible that
41 this high response was due to patient demographics (e.g. age, social background or current
42 use of contraception) and patients considering their family already complete. Indeed, a
43 higher proportion of older patients recorded 'other' reasons for not discussing FPP issues
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 with their doctor compared to younger patients. Patient emotions was an important theme
4 identified for online discussions, perhaps particularly relevant for those with a history of
5 miscarriage/stillbirth or infertility problems, and it should also be considered that such
6 associations could be a factor underlying why some patients reported that they did not
7 discuss FPP with their physician for 'other' reasons.
8
9
10
11
12

13
14
15
16 Of key importance, many female patients of child-bearing age reported that they did not feel
17 that their concerns relating to FPP in the context of their disease were adequately addressed
18 during their medical appointments. There was some variability in patient response across
19 countries to this question, suggesting that cultural differences and differences in healthcare
20 system structure may contribute to the variability in patient satisfaction. However, it is clear
21 that there can be a definite improvement in the response to these issues and all healthcare
22 professionals should consider how they could increase such communication and support to
23 their patients. This could include provision of better patient educational material and advice
24 on reliable and up-to-date websites containing FPP-related information. Indeed, patients
25 reported that they frequently sought information online, although specific condition-related
26 forums/patient organisations did not appear to be common sources of this information.
27
28 Furthermore, the online landscape was fragmented by disease area, with no specific
29 resource (beyond "Motherisk"; www.motherisk.org) that provides FPP guidance on common
30 autoimmune conditions and medication use affecting women in the reproductive age group.
31 As such, development of a single site with consistent up-to-date guidance covering topics
32 identified by patients as key interests would probably be of great value. Alternatively patient
33 and/or physician organisations could incorporate more detailed information and advice on
34 their websites to offer improved support to concerned patients and the various physicians
35 involved in their care during pregnancy. Another key improvement would be increased
36 dialogue, by telephone, letters or e-mail, between the varied physicians involved in an
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 individual patient's care in order to provide coordinated advice and support. Together these
4
5 measures would aim to improve patient support and satisfaction.
6
7

8
9 It should be noted that this study does have some limitations. Two important limitations of
10
11 the patient survey were an absence of formal survey validation and the reliance upon self-
12
13 reporting of diagnosis by patients. It should also be considered that patients who are willing
14
15 and motivated to complete a questionnaire may differ significantly from the overall patient
16
17 population. Furthermore, even though the surveys were translated into local languages,
18
19 differences in terminology and healthcare system structure exist across countries which
20
21 could impact pooling of results; for example, the terms obstetrician and gynaecologist could
22
23 be understood as being interchangeable in some countries but distinctly different specialties
24
25 in others meaning patient interpretation of the survey could vary. The physician survey may
26
27 also suffer related issues. In addition, the physician survey was only delivered to
28
29 gastroenterologists in the USA and did not investigate the activities of these physicians in
30
31 other countries. The range of experience amongst physicians was also broad which,
32
33 although providing good coverage of routine clinical practice, could be complicated by
34
35 differences in attitudes between physicians of different generations. A limitation of the
36
37 current study is an inability to tease out any potential influence these factors may have on
38
39 variation in the results. The netnography research may have been limited by use of
40
41 keywords common to one country/region but different in others (e.g. 'fertility' vs 'infertility')
42
43 which could have restricted comprehensive analysis of the online landscape and patient
44
45 discussions. Finally, this study did not investigate the related concerns of men suffering from
46
47 inflammatory disease who may be using chronic medication and also considering a family;
48
49 indeed this population is often understudied and may need improved support.
50
51
52
53
54
55
56
57
58
59
60

1
2
3 In summary, FPP are extremely important issues for female patients of child-bearing age
4 who live with chronic inflammatory disease. A summary of key considerations, highlighted
5 by the results from the current study, for all physicians involved in the treatment of this
6 often neglected group of patients is presented in Figure 5. It is clear that female patients of
7 child-bearing age do wish to discuss these issues with their physicians although expectations
8 regarding frequency of discussion and their preferred physician for advice vary considerably.
9 Currently it appears that more can be done to provide these patients with consistent and co-
10 ordinated information regarding their disease and how it, and associated treatments, could
11 affect conception or pregnancy. Results from this study suggest physicians should regularly
12 initiate discussion of these topics with their female patients of child-bearing age, particularly
13 those on chronic medication or when changes to the treatment plan could impact pregnancy
14 outcome, in order to improve patient support. In addition, greater cross-speciality
15 communication between physicians involved in different aspects of the patient's care, from
16 gastroenterologists and rheumatologists to gynaecologists/obstetricians and GPs, is needed
17 to improve the consistency of advice offered to this often overlooked patient population.
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Acknowledgements

This publication has been funded by UCB Pharma. The authors acknowledge InSites Consulting and ACROSS HEALTH for survey development, management and analysis. The authors also acknowledge Costello Medical Consulting for editorial and administrative support.

Funding Statement

This work was supported by UCB Pharma

Competing Interests Statement

EC has previously been reimbursed by UCB Pharma for consultation services; MEBC has previously been reimbursed by UCB Pharma for consultation services; DSP is an employee of UCB Pharma; SM is an employee of UCB Pharma; CG declared no competing interests.

Author Contributions

EC: substantial contribution to conception and design, interpretation of data, drafting and critical revision of the manuscript, and final approval of the manuscript for submission.

MEBC: substantial contribution to conception and design, interpretation of data, drafting and critical revision of the manuscript, and final approval of the manuscript for submission.

DSP: substantial contribution to conception and design, interpretation of data, drafting and critical revision of the manuscript, and final approval of the manuscript for submission.

SM: substantial contribution to conception and design, acquisition, analysis and interpretation of data, critical revision of the manuscript, and final approval of the manuscript for submission.

CG: substantial contribution to conception and design, interpretation of data, drafting and critical revision of the manuscript, and final approval of the manuscript for submission.

References

1. Symmons D, Turner G, Webb R, et al. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. *Rheumatology* 2002;41(7):793-800.
2. Symmons DP. Epidemiology of rheumatoid arthritis: determinants of onset, persistence and outcome. *Best practice & research. Clinical rheumatology* 2002;16(5):707-22.
3. Carbone LD, Cooper C, Michet CJ, et al. Ankylosing spondylitis in Rochester, Minnesota, 1935-1989. Is the epidemiology changing? *Arthritis and rheumatism* 1992;35(12):1476-82.
4. J. S, J. B. *Ankylosing Spondylitis in Clinical Practice*: Springer-Verlag London Limited, 2011.
5. Binder V. Epidemiology of IBD during the twentieth century: an integrated view. *Best practice & research. Clinical gastroenterology* 2004;18(3):463-79.
6. Gollop JH, Phillips SF, Melton LJ, et al. Epidemiologic aspects of Crohn's disease: a population based study in Olmsted County, Minnesota, 1943-1982. *Gut* 1988;29(1):49-56.
7. Loftus EV, Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. *Gastroenterology* 2004;126(6):1504-17.
8. Klippel JH. Systemic lupus erythematosus: demographics, prognosis, and outcome. *The Journal of rheumatology. Supplement* 1997;48:67-71.
9. Bush MC, Patel S, Lapinski RH, et al. Perinatal outcomes in inflammatory bowel disease. *The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet* 2004;15(4):237-41.
10. Morales M, Berney T, Jenny A, et al. Crohn's disease as a risk factor for the outcome of pregnancy. *Hepato-gastroenterology* 2000;47(36):1595-8.

- 1
2
3 11. Ostensen M. Sex hormones and pregnancy in rheumatoid arthritis and systemic lupus
4 erythematosus. *Annals of the New York Academy of Sciences* 1999;876:131-43;
5
6 discussion 44.
7
8
- 9
10 12. Baird DD, Narendranathan M, Sandler RS. Increased risk of preterm birth for women
11 with inflammatory bowel disease. *Gastroenterology* 1990;99(4):987-94.
12
- 13 13. van Dunne FM, Lard LR, Rook D, et al. Miscarriage but not fecundity is associated with
14 progression of joint destruction in rheumatoid arthritis. *Annals of the rheumatic*
15 *diseases* 2004;63(8):956-60.
16
17
- 18 14. Jawaheer D, Zhu JL, Nohr EA, et al. Time to pregnancy among women with rheumatoid
19 arthritis. *Arthritis and rheumatism* 2011;63(6):1517-21.
20
21
- 22 15. Mayberry JF, Weterman IT. European survey of fertility and pregnancy in women with
23 Crohn's disease: a case control study by European collaborative group. *Gut*
24 1986;27(7):821-5.
25
26
- 27 16. Manosa M, Navarro-Llavat M, Marin L, et al. Fecundity, pregnancy outcomes, and
28 breastfeeding in patients with inflammatory bowel disease: a large cohort survey.
29 *Scandinavian journal of gastroenterology* 2013;48(4):427-32.
30
31
- 32 17. Vermeire S, Carbonnel F, Coulie PG, et al. Management of inflammatory bowel disease in
33 pregnancy. *Journal of Crohn's & colitis* 2012;6(8):811-23.
34
35
- 36 18. Mahadevan U, Cucchiara S, Hyams JS, et al. The London Position Statement of the
37 World Congress of Gastroenterology on Biological Therapy for IBD with the European
38 Crohn's and Colitis Organisation: pregnancy and pediatrics. *The American journal of*
39 *gastroenterology* 2011;106(2):214-23; quiz 24.
40
41
- 42 19. Ng SW, Mahadevan U. Management of inflammatory bowel disease in pregnancy. *Expert*
43 *review of clinical immunology* 2013;9(2):161-74.
44
45
- 46 20. Ostensen M, Forger F. Management of RA medications in pregnant patients. *Nature*
47 *reviews. Rheumatology* 2009;5(7):382-90.
48
49

- 1
2
3 21. Syme MR, Paxton JW, Keelan JA. Drug transfer and metabolism by the human placenta.
4
5 *Clinical pharmacokinetics* 2004;43(8):487-514.
6
7 22. Buckley LM, Bullaboy CA, Leichtman L, et al. Multiple congenital anomalies associated
8
9 with weekly low-dose methotrexate treatment of the mother. *Arthritis and*
10
11 *rheumatism* 1997;40(5):971-3.
12
13 23. Lloyd ME, Carr M, McElhatton P, et al. The effects of methotrexate on pregnancy, fertility
14
15 and lactation. *QJM : monthly journal of the Association of Physicians*
16
17 1999;92(10):551-63.
18
19 24. Brent RL. Teratogen update: reproductive risks of leflunomide (Arava); a pyrimidine
20
21 synthesis inhibitor: counseling women taking leflunomide before or during pregnancy
22
23 and men taking leflunomide who are contemplating fathering a child. *Teratology*
24
25 2001;63(2):106-12.
26
27 25. Chakravarty EF, Sanchez-Yamamoto D, Bush TM. The use of disease modifying
28
29 antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a
30
31 survey of practice patterns and pregnancy outcomes. *The Journal of rheumatology*
32
33 2003;30(2):241-6.
34
35 26. Langen ES, Chakravarty EF, Liaquat M, et al. High Rate of Preterm Birth in Pregnancies
36
37 Complicated by Rheumatoid Arthritis. *American journal of perinatology* 2013.
38
39 27. Hameen-Anttila K, Jyrkka J, Enlund H, et al. Medicines information needs during
40
41 pregnancy: a multinational comparison. *BMJ open* 2013;3(4).
42
43 28. Peters SL, Lind JN, Humphrey JR, et al. Safe lists for medications in pregnancy:
44
45 inadequate evidence base and inconsistent guidance from Web-based information,
46
47 2011. *Pharmacoepidemiology and drug safety* 2013;22(3):324-8.
48
49 29. Toomey D, Waldron B. Family planning and inflammatory bowel disease: the patient and
50
51 the practitioner. *Family practice* 2013;30(1):64-8.
52
53
54
55
56
57
58
59
60

- 1
2
3 30. van der Woude CJ, Kolacek S, Dotan I, et al. European evidenced-based consensus on
4 reproduction in inflammatory bowel disease. *Journal of Crohn's & colitis*
5 2010;4(5):493-510.
6
7
8
9 31. Finer LB, Henshaw SK. Disparities in rates of unintended pregnancy in the United States,
10 1994 and 2001. *Perspectives on sexual and reproductive health* 2006;38(2):90-6.
11
12
13 32. Panchal S, Khare M, Moorthy A, et al. Catch me if you can: a national survey of
14 rheumatologists and obstetricians on the use of DMARDs during pregnancy.
15 *Rheumatology international* 2013;33(2):347-53.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Figure 1.** Frequency of physician-initiated discussions regarding FPP issues with female
4 patients and their GPs or gynaecologists (survey Phase 2 data shown in B and C)

5
6
7 *Abbreviations:* Ga = gastroenterologist; Rh = rheumatologist. * $p < 0.05$ compared to Phase 1
8
9 (two-sided z-test with significance level 0.05)
10

11
12
13 **Figure 2.** Patient reported (patient survey) topics of discussion with specialist physicians,
14 the frequency of patient-initiated FPP discussion and the importance of FPP issues stratified
15 by patient age (data from survey Phase 2 shown in C)
16
17

18
19
20
21
22 **Figure 3.** Patient preference for frequency of discussions relating to FPP issues and
23 identification of issues that prevented discussion (data from patient survey Phase 2 shown)
24
25

26
27
28 **Figure 4.** Patient preference for choice of healthcare provider for discussions of their
29 condition and FPP issues, and their preferred source of additional information (outside
30 doctors' office/clinic/surgery) relating to both their condition and FPP issues (data from
31 patient survey Phase 2 shown)
32
33
34

35
36
37
38 **Figure 5.** FPP-related considerations for practicing physicians treating female patients of
39 child-bearing age who live with chronic inflammatory disease: key messages from the survey
40 of current clinical practice and patient perceptions.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Family Planning and Pregnancy Issues for Women with Systemic Inflammatory**
4
5 **Diseases: Patient and Physician Perspectives**
6
7
8

9 Eliza Chakravarty,¹ Megan E.B. Clowse,² Daphnee S. Pushparajah,³ Sarah Mertens,³ Caroline
10
11 Gordon⁴
12
13

14
15
16 ¹Oklahoma Medical Research Foundation, Oklahoma City, USA

17
18 ²Duke University Medical Center, Durham, USA

19
20 ³UCB Pharma, Brussels, Belgium

21
22 ⁴School of Immunity and Infection, College of Medical and Dental Sciences, University of
23
24 Birmingham, Birmingham, UK
25
26
27

28
29 **Correspondence to:**

Dr Eliza Chakravarty
Arthritis & Clinical Immunology Research Program, MS 50
Oklahoma Medical Research Foundation
825 N.E. 13th Street
Oklahoma City
OK 73104
USA
Telephone: +1 (405) 271-6042
Fax: +1 (405) 271-2319
Email: Eliza-Chakravarty@omrf.org

30
31
32
33
34
35
36
37
38
39
40
41
42 **Key Words**

43
44
45 Autoimmune Disease, Inflammatory Disease, Pregnancy, Family Planning
46
47
48

49
50 **Word Count:** 4,139
51
52

53
54 **Funding Statement**

55
56 This work was supported by UCB Pharma
57
58
59
60

Competing Interests Statement

EC has previously been reimbursed by UCB Pharma for consultation services; MEBC has previously been reimbursed by UCB Pharma for consultation services; DSP is an employee of UCB Pharma; SM is an employee of UCB Pharma; CG declared no competing interests.

Author Contributions

EC: substantial contribution to conception and design, interpretation of data, drafting and critical revision of the manuscript, and final approval of the manuscript for submission.

MEBC: substantial contribution to conception and design, interpretation of data, drafting and critical revision of the manuscript, and final approval of the manuscript for submission.

DSP: substantial contribution to conception and design, interpretation of data, drafting and critical revision of the manuscript, and final approval of the manuscript for submission.

SM: substantial contribution to conception and design, acquisition, analysis and interpretation of data, critical revision of the manuscript, and final approval of the manuscript for submission.

CG: substantial contribution to conception and design, interpretation of data, drafting and critical revision of the manuscript, and final approval of the manuscript for submission.

Abstract

Objectives: To identify family planning and pregnancy (FPP) issues for female patients of child-bearing age living with a chronic inflammatory disease and to assess whether current clinical practice routinely provides adequate support to alleviate these concerns.

Setting: Multinational survey and an analysis of online patient activity.

Participants: Premenopausal women (aged 20-45 years of age; N=969) were surveyed in USA, UK, Germany, France, Italy and Spain. Rheumatologists were surveyed in Germany (N=50), France (N=50), Italy (N=50) and the USA (N=100) and gastroenterologists were also surveyed in the USA (N=100).

Primary and Secondary Outcome Measures: Two online surveys were undertaken to identify FPP issues for both physicians and patients. The surveys examined the frequency of dialogue on these topics between physicians and patients, alongside assessment of patient satisfaction regarding these conversations. Online analysis identified key themes for patient discussion outside their doctors' office/clinic/surgery.

Results: 32-56% of physicians spontaneously reported having talked about FPP with their female patients of child-bearing age. When prompted, the majority of rheumatologists (74-92%) and gastroenterologists (74%) reported having discussed conception/pregnancy with female patients; however, less than half reported consulting their patient's treating GP/gynaecologist about these topics.

1
2
3 The majority of patients reported their FPP-related concerns are not adequately
4
5 addressed/settled during their medical appointments. Furthermore, only 30-40% of patients
6
7 considered advice/information to be consistent across multiple healthcare professionals.
8
9

10
11 Key online FPP-related patient discussions included: disease state, adverse effects,
12
13 treatment, switch behaviour and wash-out requirements.
14
15

16
17
18 **Conclusions:** Female patients who live with chronic inflammatory disease have important
19
20 FPP concerns. The majority of patients, however, do not feel that their FPP concerns are
21
22 adequately addressed in current clinical practice and report that they receive inconsistent
23
24 advice from the various healthcare professionals who manage different aspects of their care.
25
26 There is a clear need for provision of up-to-date and consistent information/support to
27
28 female patients.
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Article Summary

Article Focus:

- To identify key family planning and pregnancy (FPP) issues for female patients of child-bearing age who live with a chronic inflammatory disease and to assess whether current clinical practice routinely provides adequate support to alleviate these concerns.

Key Messages:

- Female patients of child-bearing years wish to discuss FPP issues in relation to their disease with their physicians but the majority of female patients who live with chronic inflammatory disease feel that their concerns are not adequately addressed.
- Physicians should initiate discussion of FPP issues with their female patients, particularly those receiving immunosuppressive treatment up to the ages of 50, and establish their expectations and concerns.
- Treating physicians should work to maintain this dialogue, at least once per year or when treatment changes, and align the advice offered to their female patients of child-bearing age with that from other physicians involved in their care.

Strengths and Limitations:

- Strengths: investigation of both patient and physician perspectives, involvement of specialists from different areas of interest and cross-cultural investigation.
- Limitations: absence of formal survey validation, reliance upon patient self-reporting, complications associated with delivery of the survey in local languages and possible bias in netnography research due to regional differences in language usage.

Introduction

Autoimmune and inflammatory diseases often affect women of reproductive age. Although RA becomes more common as patients age,¹ women are increasingly choosing to start their family later in life and treatments to control RA are now often started at a younger age. Moreover, even though only a minority proportion of RA patients are women of child-bearing age,² the high prevalence of the disease means that it does impact a significant number of young women. Many other inflammatory diseases, including ankylosing spondylitis (AS),^{3 4} Crohn's disease (CD),^{5 6} inflammatory bowel disease (IBD)⁷ and systemic lupus erythematosus (SLE),⁸ also affect a younger population and thus have a direct effect on women of child-bearing age.

Pregnancy and child rearing are important facets of life for most women. Now that improved therapies for inflammatory diseases have enabled better physical function and quality of life, many women who previously would have felt too ill to consider child-bearing are now better able to fulfil desires for family life. Family planning and pregnancy (FPP) are also important issues for this patient population as ~~multiple studies have linked~~ these disease states have been linked to an increased risk of adverse pregnancy outcomes,⁹⁻¹¹ including increased risk of preterm birth,¹² ~~decreased chance of conceiving,~~¹² difficulty carrying to full term¹³ and a possible reduction in fertility,^{14 15} although there is conflicting evidence regarding the impact of inflammatory diseases on fertility.^{16 17} ~~increasing the risk of other potential complications.~~⁹⁻¹¹ Due to this the impact on pregnancy outcomes, expert advice is to achieve and maintain stable low disease activity prior to conception and throughout pregnancy.¹⁸⁻²⁰ Some anti-inflammatory treatment options can be potentially hazardous for pregnant women to take as drugs can pass across the placenta and may affect the foetus.²¹ Methotrexate, a common RA treatment, can be damaging to foetal

1
2
3 development (at least at high doses)^{22 23} whilst other disease-modifying anti-rheumatic drugs
4
5 such as leflunomide have been shown to cause malformations in animal studies.²⁴
6
7

8
9 However, use of medications during pregnancy is not always contraindicated and an
10
11 individual risk-benefit discussion should be undertaken between the patient and expert
12
13 physician to provide the best management of both the disease and the pregnancy.²⁵
14

15 Inadequate dissemination of appropriate advice describing which drugs may be continued
16
17 can lead to women unnecessarily forgoing potentially helpful medications and thus suffering
18
19 throughout pregnancy, with the increased risk of further complications to both mother and
20
21 child due to the effects of active disease.²⁶ Furthermore, patients are increasingly seeking
22
23 additional information on the internet,²⁷ while a recent analysis of information regarding
24
25 medication safety on active internet sites has noted an inadequate evidence base for the
26
27 advice often provided and inconsistent guidance.²⁸ It is clear that communication of reliable
28
29 and consistent information is required to enable the correct treatment of these women
30
31 before and during pregnancy, and while breast-feeding. Education and information should
32
33 be shared by healthcare professionals dealing with these diseases, medications and
34
35 situations on a daily basis. Accurate, consistent information must be communicated to
36
37 women considering or entering pregnancy in order to support patients through this delicate
38
39 journey.
40
41
42
43
44

45 Two surveys were undertaken to investigate some of these issues, one of physicians and
46
47 another of female patients, to identify the key concerns of both groups related to the topics
48
49 of FPP in inflammatory disease. The surveys were designed to gauge whether there is a gap
50
51 in the communication between what healthcare professionals provide in terms of
52
53 information/support and what patients feel that they receive. The patient survey also
54
55 investigated where patients go to seek additional information. Two key objectives of the
56
57
58
59
60

1
2
3 study were to examine the proportion of physicians who discuss FPP issues with their female
4 patients of child-bearing age and the proportion of patients who have discussed these
5 topics, in the context of their condition, with their healthcare professional. The survey also
6 assessed the proportion of patients who feel that their concerns on this topic have been
7 satisfactorily addressed by these discussions. Here we aim to communicate the insights
8 gained from this investigation to clinicians treating women of child-bearing age, who live
9 with chronic inflammatory conditions, in order to provide advice on how best to support
10 these patients.
11
12
13
14
15
16
17
18
19
20
21

22 **Methods**

23
24 This study complied with the ICC/ESOMAR, EphMRA, ABPI, MRS and BHBIA market research
25 codes of conduct, ensuring the anonymity and confidentiality of all participants.
26

27
28 Respondents were paid a nominal amount, calculated using fair market value guidance, to
29 compensate for the time and effort of completing the survey.
30
31
32

33 *Physician Survey*

34
35 The online physician questionnaire was delivered in two phases, the first phase (baseline)
36 was distributed in July 2012 (Europe) and September 2012 (USA), and the second phase
37 was distributed in November 2012 in both Europe and USA. The survey was delivered in the
38 local language and translations were checked for consistency against the original in English
39 by native speakers with fluency in both languages (the complete Physician Questionnaire
40 can be found online in Appendix 1). The questionnaire was designed to elicit both
41 spontaneous (open-ended question) and prompted (closed question in which FPP topics
42 were an option among other answering categories) responses. Participants were recruited
43 from the WorldOne Physician Panel. Rheumatologists were surveyed in four countries:
44 Germany (N=50), France (N=50), Italy (N=50) and the USA (N=100). Gastroenterologists
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 were surveyed in the USA (N=100). Responses were compared between phases using two-
4
5 sided z-tests with significance level 0.05, which corresponds to a confidence interval of 95%.
6
7

8
9 Participating physicians had to meet the following criteria: 3 to 30 years of experience,
10
11 $\geq 50\%$ patient-facing time, had not participated in medical research within their specialist
12
13 area in the past month, were not currently a clinical investigator for a pharmaceutical
14
15 manufacturer and were not currently active in medical research or advertising (to avoid
16
17 inclusion of respondents motivated only by receipt of payment). Physicians with
18
19 Rheumatology as their primary specialty had to meet the following additional criteria: treat
20
21 ≥ 20 RA patients per month and have ≥ 10 patients on biologics per month. Physicians with
22
23 Gastroenterology as their primary specialty had to meet the following additional criteria:
24
25 treat ≥ 8 CD patients per month and have ≥ 2 patients on biologics per month. These
26
27 selection criteria were applied to ensure participating physicians had sufficient experience
28
29 treating patients with systemic inflammatory disease in order to provide informative results,
30
31 while also seeking to include physicians with a range of experience in order to investigate
32
33 routine clinical practice.
34
35
36
37
38

39 *Patient Survey*

40
41 The online patient questionnaire was designed according to standard market research
42
43 survey methodology, including scaling questions and avoiding skewed questions. The
44
45 questionnaire was delivered in the local language and translations were checked for
46
47 consistency against the original in English by native speakers with fluency in both languages
48
49 (the complete Patient Questionnaire can be found online in Appendix 2). The questionnaire
50
51 was targeted at premenopausal women (age was self-declared and the survey excluded
52
53 women under 20 and over 45 years of age; see Question 3 Patient Survey). A professional
54
55 recruitment agency was used to recruit patients from the GlobalTestMarket and MySurvey
56
57
58
59
60

online survey panels. Respondents were screened according to age, gender and disease (all self-reported) and those who were <20 or >45 years old, male, or not suffering from RA, CD or lupus were excluded. Recruited patients were then sent a link to an online survey, which was followed up by a short telephone interview at a pre-arranged time.

The patient questionnaire was delivered in two phases and was distributed in six countries (USA, UK, Germany, France, Italy and Spain). The first phase (baseline) consisted of 16 questions and was disseminated to patients between 17th July and 15th August 2012. There were 1,069 respondents to the first phase which covered patients with RA, SLE, CD and ulcerative colitis (UC). The second phase consisted of the original 16 questions from the first phase plus an additional 8 questions included in order to avoid so-called 'false positives' (i.e. covered topics included in other questions to test consistency of response) and to provide greater insight into patients' experience in terms of medical care and needs. The second phase elicited 969 responses and was distributed between 13th October and 16th November 2012 to patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA), in addition to RA, SLE, CD and UC patients. All responses were anonymous. The patients who were invited to participate in the two survey phases were not identical, although there may have been some overlap (responses were anonymous therefore the extent of overlap could not be determined).

Netnography Research

Online discussions (English language only) relating to FPP issues were investigated using two approaches: social media monitoring, and search engine landscape/content analysis (SELA).

1
2
3 Social media monitoring was undertaken by identifying categories of interest (defined as:
4
5 'ulcerative colitis', 'systemic lupus erythematosus', 'rheumatoid arthritis', 'colitis ulcerosa',
6
7 'lupus', 'regional enteritis', 'Crohn's disease') and keywords of interest (defined as:
8
9 'pregnancy', 'miscarriage', 'birth control', 'miscarriages', 'fertile', 'family planning', 'gestation',
10
11 'pregnant', 'fertility', 'pregnancy disease evolution', 'disease transfer to baby', 'breastfeeding',
12
13 'breast feeding', 'conception', 'conceived' and 'placental transfer'), and then combining
14
15 keywords together with the categories of interest to ensure coverage of all topics of interest.
16
17

18
19
20 SELA methodology involved identification of keywords (including generic keywords/keyword
21
22 phrases and specific keywords/keyword phrases), assessment of keyword search volume
23
24 and ranking of individual sites in search engine results. The 'click through rate' was
25
26 combined with the 'monthly search volume' to estimate the 'share of attention index'. The
27
28 final keyword pool included the categories 'colitis ulcerosa', 'ulcerative colitis', 'Crohn's
29
30 disease', 'lupus', 'rheumatoid arthritis', 'regional enteritis' and 'systemic lupus
31
32 erythematosus', and the following FPP-related keywords 'gestation', 'birth control',
33
34 'pregnancy', 'fertility', 'miscarriage' and 'family planning'.
35
36
37
38

39 **Results**

40 *Physician Survey*

41
42 Many rheumatologists and gastroenterologists spontaneously reported having discussed
43
44 FPP-related topics with their female patients of child-bearing age; reports were consistent
45
46 across all countries studied (Figure 1A). Interestingly, the number of US gastroenterologists
47
48 who discussed these topics with their female patients increased significantly between the
49
50 first and second Phases of the survey (Figure 1A). This was particularly true for fertility,
51
52 pregnancy and/or family planning issues specifically, in which the percentage of US
53
54 gastroenterologists discussing these topics increased from 67% to 79% between the two
55
56
57
58
59
60

1
2
3 Phases (significant difference, 95% confidence level; N=100 for both survey phases);
4
5 however there was no difference in European practice, with levels remaining at 60%.
6
7

8
9 When prompted, the majority of rheumatologists (74-92%) and gastroenterologists (74%)
10 reported having discussed conception/pregnancy with female patients of child-bearing age.
11
12 However, less than half of these physicians discussed FPP related issues with their patient's
13 treating GP (i.e. primary care physician) or gynaecologist (Figure 1B and Figure 1C; survey
14 Phase 2 data shown; see Questions 20 and 21 Physician Survey Appendix 1).
15
16
17
18
19

20
21
22 When seeking additional information regarding FPP, community rheumatologists and
23 gastroenterologists reported currently relying on presentations and educational events at
24 congresses, other healthcare professionals and key opinion leaders as their preferred
25 sources of information.
26
27
28
29

30 31 32 *Patient Survey and Netnography Analysis*

33
34 Patients reported that the frequency of FPP-related conversations during their medical
35 appointments was lower than their discussions about emotional well-being and employment
36
37 (Figure 2A), although most female patients of child-bearing age (~~up to 85%~~) reported
38 discussing these issues at some point during their care pathway (Figure 2B).
39
40
41
42
43
44

45
46 Patients currently on medication for the treatment of their condition reported being more
47 concerned about FPP issues than those not receiving medication, with 63% of those on
48 medication reporting that pregnancy was a concern compared to only 32% of patients not
49 receiving medication. In addition, the female age group with most concerns related to FPP
50 was between the ages of 30 and 34, ~~with >60% of these patients reporting concerns~~
51
52 (Figure 2C; survey Phase 2 data shown, similar trend observed in Phase 1). Concern was
53
54
55
56
57
58
59
60

1
2
3 high between the ages of 25 and 39 (~~57-63%~~) but decreased ~~to 44%~~ in patients aged
4
5 between 40 and 45.
6
7

8
9 Patients were asked when they would prefer to discuss the topics of FPP. The survey
10
11 revealed ~~that approximately 35% of~~ patients prefer to discuss these issues in the context of
12
13 their disease and treatment whenever a decision is made that could have an impact on their
14
15 family planning or ability to become pregnant (Figure 3A). Approximately a quarter feel that
16
17 one conversation with their healthcare professional on this topic is enough, although
18
19 ~~approximately 17% some~~ would like to discuss these topics at every visit. Furthermore,
20
21 approximately a third of patients prefer to initiate conversations on this topic themselves
22
23 ~~(30-40% patients)~~ or to obtain information from their healthcare professional when
24
25 appropriate to their individual situation ~~(15-35% patients)~~.
26
27
28

29
30 Patients gave a range of reasons for not discussing FPP concerns with their healthcare
31
32 provider, with the most common reason being that they forgot to mention it (Figure 3B).
33
34 Other important reasons identified as barriers for discussing FPP was the impression that the
35
36 healthcare professional either did not have time for discussions or that they were not the
37
38 correct physician to provide advice on these topics. Importantly, some patients also reported
39
40 that they choose to not discuss FPP issues as they were reluctant to change medication.
41
42 Very few patients felt that their healthcare professional was reluctant to discuss these
43
44 topics. Over a quarter of respondents indicated that they had 'other' reasons for not
45
46 discussing these issues with their doctor (Figure 3B). A higher proportion (39%) of patients
47
48 aged 40-45 years recorded 'other' reasons for not discussing FPP issues with their doctor,
49
50 compared to younger patients ('other' was recorded by 21.7% of 20-24 year olds, 18.3% of
51
52 25-29 year olds, 18.7% of 30-34 year olds and 25.6% 35-39 year olds).
53
54
55
56
57
58
59
60

1
2
3 Patients report a preference for seeking information regarding FPP from their gynaecologist
4 (Figure 4A), whereas disease specialists (e.g. rheumatologist or gastroenterologist) are their
5 key contact point for management of their chronic condition (Figure 4B). GPs/primary care
6 physicians were also identified by patients as central to their discussions of both FPP and
7 their chronic condition (Figure 4A-B). It should be noted, however, that patient reports of a
8 preference for one specialist over another regarding FPP discussions could be expected to
9 vary by country given differences in treatment practices. For example, in the USA patients
10 may commonly visit a gynaecologist/obstetrician for all pregnancy care whereas in the UK
11 the patient's GP and local midwife may oversee most of their pregnancy planning and
12 management. In addition, when responding to the survey some, but not all, patients may
13 have regarded the terms 'obstetrician' and 'gynaecologist' as interchangeable based on their
14 own experience.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

31 Other than their doctors' office/clinic/surgery, patients reported researching and discussing
32 information regarding FPP through multiple channels (Figure 4C): predominantly on disease-
33 related websites and with family and friends. In addition, patients reported that specific
34 condition-related forums/patient organisations did not play a prominent part in their search
35 for online information on these topics. A number of key themes, such as discussions around
36 disease state, adverse effects, treatment, switch behaviour and wash-out requirements,
37 emerged after following online patient activity. Other themes noted were patient emotions
38 and feelings, interactions with healthcare professionals, how best to identify the correct
39 healthcare professional for their treatment, concerns about inconsistent advice, infertility,
40 sexuality and conception, disease carry-over to the baby, placental transfer of treatments
41 and breastfeeding.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Importantly, approximately 30-55% of female patients reported that their concerns relating
4 to FPP are not adequately addressed or settled during their medical appointments (data
5 from patient survey Phase 2). Some variability in this response was observed across
6
7 countries, with 30% of patients from the USA, 34% from Italy, 35% from Spain, 39% from
8
9 the UK, 43% from France and 54% from Germany reporting their concerns were not settled
10
11 (data from patient survey Phase 2). Patients also reported that consistency of advice and
12
13 information given by multiple healthcare professionals, including nurses, was low with only
14
15 about 30-40% of patients reporting consistent advice. Again, responses to this question
16
17 varied across countries with 33% of patients reporting consistent advice from Spain and the
18
19 UK, 36% from Germany and Italy, 40% from the USA and 41% from France (data from
20
21 patient survey Phase 2). Inconsistent advice was reported by about 30-50% of patients
22
23 overall: 27% from Italy, 32% from Spain, 38% from France, 41% from the USA, 44% from
24
25 Germany and 49% from the UK (remaining patients selected a neutral response to this
26
27 question; data from patient survey Phase 2).
28
29
30
31
32
33
34

35 Discussion

36
37 The investigation described here was carried out to illuminate some of the issues
38
39 surrounding FPP for female patients of child-bearing age who live with chronic inflammatory
40
41 diseases. Recently it was reported that almost half of female IBD patients feel their disease
42
43 and/or treatment influences their decisions about FPP but despite this about two thirds had
44
45 not discussed these issues with their doctor.²⁹ The results from the current study confirmed
46
47 that FPP are considered important issues by this group of female patients and that there are
48
49 key gaps in communication which result in inconsistent advice and subsequent patient
50
51 concern/confusion. Importantly, the majority of female patients of child-bearing age
52
53 reported that current clinical practice does not adequately address their concerns related to
54
55 FPP in inflammatory disease.
56
57
58
59
60

1
2
3
4
5 Some clinical recommendations for the management of inflammatory disease during
6 pregnancy have been published^{18-20 25 30} and advise that clinical remission/stable low disease
7 activity be achieved prior to conception and maintained throughout pregnancy using
8 appropriate therapy as needed. However, in the current study few patients reported
9 discussing FPP at the point their condition was stable enough to become pregnant,
10 suggesting a gap in necessary communication from physicians to patients regarding the
11 need to control disease activity prior to conception, the impact of disease activity on
12 pregnancy outcomes and the need to adjust medications during pregnancy. Indeed, a
13 general lack of patient knowledge regarding continued use of medication during pregnancy
14 was highlighted recently by a survey of female IBD patients which revealed a widespread,
15 but inaccurate, belief that all medications needed to be stopped during pregnancy.²⁹
16 Respondents to the current patient survey also reported that inconsistencies in advice
17 regarding the use of anti-inflammatory and immunosuppressive medications during
18 pregnancy are common. Together, these results suggest a need for continuing education of
19 all specialists involved in the care of women with inflammatory disease in order to ensure
20 women understand the implications of their condition and treatment on FPP. Congress
21 presentations and associated education events were identified by physicians, specifically
22 rheumatologists and gastroenterologists, as their currently preferred source of information
23 and continuing education – which may also be applicable to other specialists. As such, these
24 events should be actively targeted to maximise and improve continued education. This
25 could, for example, include hosting discussion forums between specialists involved in
26 different aspects of care for these patients at international and national congresses. Timely
27 discussion of FPP issues is also an important consideration given a high percentage of
28 pregnancies are unplanned.³¹
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 GPs/primary care physicians and gynaecologists were identified by patients as frequently
4 central to their discussions on FPP issues, although research has previously shown that 41%
5 of GPs do not initiate discussion of FPP with female patients affected by IBD.²⁹ Importantly a
6 gap in communication was identified between these physicians and the specialists who treat
7 chronic inflammatory diseases. As such, improved cross-specialty communication should be
8 strongly encouraged, particularly for discussions regarding planning and treatment
9
10 guidelines. This could involve establishment of cross-specialty teams within hospitals/centres
11 of excellence to co-ordinate care of pregnant women living with systemic inflammatory
12 disease. A recent survey of GPs in Ireland did show that the majority of GPs report seeking
13 additional advice on FPP issues, in relation to their female IBD patients, from tertiary
14 specialists²⁹ so improved education for all specialties and fostering communication should
15 assist dissemination of information and consistent advice for patients. Furthermore, all of
16 those involved in the care of female patients of child-bearing age who live with chronic
17 inflammatory disease, not only the immunological disease specialists, should be exposed to
18 continued education on this topic. Another recent survey of rheumatologists and
19 obstetricians showed that there is variability in advice given to patients concerning the use
20 of specific medication during pregnancy.³² This highlights a need for consistency amongst
21 clinicians to achieve quality patient care. Development of cross-specialty international
22 guidelines/consensus papers by relevant expert physicians may help bridge these gaps in
23 communication. Furthermore, publication of evidence-based discussions of the risks and
24 benefits of medication use and disease activity control during pregnancy in women with
25 inflammatory diseases by relevant medical societies could provide an easily accessible
26 resource for physicians and patients alike. These could be in the form of "white papers" and
27 accompanying patient information pieces, published in the scientific literature and online, to
28 provide consistent education and advice for cross-specialty physicians and their patients.
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 In order to improve the dissemination of information regarding FPP to patients, it is
4 important to identify when patients prefer to receive such information and also why this
5 information may not be adequately communicated. Patient preference regarding timing of
6 discussions about FPP varied. This variability may be due to the personal nature of this
7 topic, differences in retention of information and differences in healthcare services/societal
8 norms across different countries. Patients did, however, generally report that they wished to
9 discuss FPP-related issues with their specialist physician (i.e. rheumatologist or
10 gastroenterologist) every time a decision was made that could impact upon their FPP. As
11 such, healthcare professionals should routinely consider any issues that affect fertility or
12 pregnancy and offer to have a conversation with their patient regarding these issues at
13 every clinic visit, unless it is known not to be relevant. It may also be useful to clarify patient
14 expectations for support and advice during these discussions. Patients on medication were
15 more concerned about FPP issues than those not receiving medication, as were female
16 patients between the ages of approximately 25 and 40. The high level of concern in both of
17 these groups highlights these patients as key populations requiring additional consideration,
18 although it could be argued that all women of child-bearing age should be targeted for such
19 communications.

20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41 The most common reason patients offered to explain why they did not raise FPP with their
42 healthcare provider was that they forgot to mention it during their consultation. Many also
43 stated they avoided such discussion as they did not want to change their medication,
44 implying that a fear of destabilising their disease could influence the preparedness of
45 patients to discuss FPP topics. Other key reasons identified were the impression that their
46 physician did not have time for the discussion or that they felt their treating physician was
47 not the correct physician to consult on these topics. Consequently, physicians should
48 consider periodically raising the issue themselves, particularly when treatment decisions or
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 disease activity could impact FPP plans. Notably over a quarter of respondents indicated that
4 they had 'other' reasons for not discussing these issues with their doctor. It is possible that
5 this high response was due to patient demographics (e.g. age, social background or current
6 use of contraception) and patients considering their family already complete. Indeed, a
7 higher proportion of older patients recorded 'other' reasons for not discussing FPP issues
8 with their doctor compared to younger patients. Patient emotions was an important theme
9 identified for online discussions, perhaps particularly relevant for those with a history of
10 miscarriage/stillbirth or infertility problems, and it should also be considered that such
11 associations could be a factor underlying why some patients reported that they did not
12 discuss FPP with their physician for 'other' reasons.
13
14
15
16
17
18
19
20
21
22
23

24
25
26 Of key importance, many female patients of child-bearing age reported that they did not feel
27 that their concerns relating to FPP in the context of their disease were adequately addressed
28 during their medical appointments. There was some variability in patient response across
29 countries to this question, suggesting that cultural differences and differences in healthcare
30 system structure may contribute to the variability in patient satisfaction. However, it is clear
31 that there can be a definite improvement in the response to these issues and all healthcare
32 professionals should consider how they could increase such communication and support to
33 their patients. This could include provision of better patient educational material and advice
34 on reliable and up-to-date websites containing FPP-related information. Indeed, patients
35 reported that they frequently sought information online, although specific condition-related
36 forums/patient organisations did not appear to be common sources of this information.
37
38
39

40
41 Furthermore, the online landscape was fragmented by disease area, with no specific
42 resource (beyond "Motherisk"; www.motherisk.org) that provides FPP guidance on common
43 autoimmune conditions and medication use affecting women in the reproductive age group.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 identified by patients as key interests would probably be of great value. Alternatively patient
4
5 and/or physician organisations could incorporate more detailed information and advice on
6
7 their websites to offer improved support to concerned patients and the various physicians
8
9 involved in their care during pregnancy. Another key improvement would be increased
10
11 dialogue, by telephone, letters or e-mail, between the varied physicians involved in an
12
13 individual patient's care in order to provide coordinated advice and support. Together these
14
15 measures would aim to improve patient support and satisfaction.
16
17

18
19
20 It should be noted that this study does have some limitations. Two important limitations of
21
22 the patient survey were an absence of formal survey validation and the reliance upon self-
23
24 reporting of diagnosis by patients. It should also be considered that patients who are willing
25
26 and motivated to complete a questionnaire may differ significantly from the overall patient
27
28 population. Furthermore, even though the surveys were translated into local languages,
29
30 differences in terminology and healthcare system structure exist across countries which
31
32 could impact pooling of results; for example, the terms obstetrician and gynaecologist could
33
34 be understood as being interchangeable in some countries but distinctly different specialties
35
36 in others meaning patient interpretation of the survey could vary. The physician survey may
37
38 also suffer related issues. In addition, the physician survey was only delivered to
39
40 gastroenterologists in the USA and did not investigate the activities of these physicians in
41
42 other countries. The range of experience amongst physicians was also broad which,
43
44 although providing good coverage of routine clinical practice, could be complicated by
45
46 differences in attitudes between physicians of different generations. A limitation of the
47
48 current study is an inability to tease out any potential influence these factors may have on
49
50 variation in the results. The netnography research may have been limited by use of
51
52 keywords common to one country/region but different in others (e.g. 'fertility' vs 'infertility')
53
54 which could have restricted comprehensive analysis of the online landscape and patient
55
56
57
58
59
60

1
2
3 discussions. Finally, this study did not investigate the related concerns of men suffering from
4
5 inflammatory disease who may be using chronic medication and also considering a family;
6
7 indeed this population is often understudied and may need improved support.
8
9

10
11 In summary, FPP are extremely important issues for female patients of child-bearing age
12
13 who live with chronic inflammatory disease. A summary of key considerations, highlighted
14
15 by the results from the current study, for all physicians involved in the treatment of this
16
17 often neglected group of patients is presented in Figure 5. It is clear that female patients of
18
19 child-bearing age do wish to discuss these issues with their physicians although expectations
20
21 regarding frequency of discussion and their preferred physician for advice vary considerably.
22
23 Currently it appears that more can be done to provide these patients with consistent and co-
24
25 ordinated information regarding their disease and how it, and associated treatments, could
26
27 affect conception or pregnancy. Results from this study suggest physicians should regularly
28
29 initiate discussion of these topics with their female patients of child-bearing age, particularly
30
31 those on chronic medication or when changes to the treatment plan could impact pregnancy
32
33 outcome, in order to improve patient support. In addition, greater cross-speciality
34
35 communication between physicians involved in different aspects of the patient's care, from
36
37 gastroenterologists and rheumatologists to gynaecologists/obstetricians and GPs, is needed
38
39 to improve the consistency of advice offered to this often overlooked patient population.
40
41
42
43
44

45 **Acknowledgements**

46
47 This publication has been funded by UCB Pharma. The authors acknowledge InSites
48
49 Consulting and ACROSS HEALTH for survey development, management and analysis. The
50
51 authors also acknowledge Costello Medical Consulting for editorial and administrative
52
53 support.
54
55
56
57
58
59
60

References

1. Symmons D, Turner G, Webb R, Asten P, Barrett E, Lunt M, et al. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. *Rheumatology* 2002;41(7):793-800.
2. Symmons DP. Epidemiology of rheumatoid arthritis: determinants of onset, persistence and outcome. *Best practice & research. Clinical rheumatology* 2002;16(5):707-22.
3. Carbone LD, Cooper C, Michet CJ, Atkinson EJ, O'Fallon WM, Melton LJ, 3rd. Ankylosing spondylitis in Rochester, Minnesota, 1935-1989. Is the epidemiology changing? *Arthritis and rheumatism* 1992;35(12):1476-82.
4. J. S, J. B. *Ankylosing Spondylitis in Clinical Practice*: Springer-Verlag London Limited, 2011.
5. Binder V. Epidemiology of IBD during the twentieth century: an integrated view. *Best practice & research. Clinical gastroenterology* 2004;18(3):463-79.
6. Gollop JH, Phillips SF, Melton LJ, 3rd, Zinsmeister AR. Epidemiologic aspects of Crohn's disease: a population based study in Olmsted County, Minnesota, 1943-1982. *Gut* 1988;29(1):49-56.
7. Loftus EV, Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. *Gastroenterology* 2004;126(6):1504-17.
8. Klippel JH. Systemic lupus erythematosus: demographics, prognosis, and outcome. *The Journal of rheumatology. Supplement* 1997;48:67-71.
9. Bush MC, Patel S, Lapinski RH, Stone JL. Perinatal outcomes in inflammatory bowel disease. *The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet* 2004;15(4):237-41.
10. Morales M, Berney T, Jenny A, Morel P, Extermann P. Crohn's disease as a risk factor for the outcome of pregnancy. *Hepato-gastroenterology* 2000;47(36):1595-8.

- 1
2
3 11. Ostensen M. Sex hormones and pregnancy in rheumatoid arthritis and systemic lupus
4 erythematosus. *Annals of the New York Academy of Sciences* 1999;876:131-43;
5 discussion 44.
6
7
- 8
9 12. Baird DD, Narendranathan M, Sandler RS. Increased risk of preterm birth for women
10 with inflammatory bowel disease. *Gastroenterology* 1990;99(4):987-94.
11
- 12 13. van Dunne FM, Lard LR, Rook D, Helmerhorst FM, Huizinga TW. Miscarriage but not
13 fecundity is associated with progression of joint destruction in rheumatoid arthritis.
14 *Annals of the rheumatic diseases* 2004;63(8):956-60.
15
- 16 14. Jawaheer D, Zhu JL, Nohr EA, Olsen J. Time to pregnancy among women with
17 rheumatoid arthritis. *Arthritis and rheumatism* 2011;63(6):1517-21.
18
- 19 15. Mayberry JF, Weterman IT. European survey of fertility and pregnancy in women with
20 Crohn's disease: a case control study by European collaborative group. *Gut*
21 1986;27(7):821-5.
22
- 23 16. Manosa M, Navarro-Llavat M, Marin L, Zabana Y, Cabre E, Domenech E. Fecundity,
24 pregnancy outcomes, and breastfeeding in patients with inflammatory bowel disease:
25 a large cohort survey. *Scandinavian journal of gastroenterology* 2013;48(4):427-32.
26
- 27 17. Vermeire S, Carbonnel F, Coulie PG, Geenen V, Hazes JM, Masson PL, et al.
28 Management of inflammatory bowel disease in pregnancy. *Journal of Crohn's &*
29 *colitis* 2012;6(8):811-23.
30
- 31 18. Mahadevan U, Cucchiara S, Hyams JS, Steinwurz F, Nuti F, Travis SP, et al. The London
32 Position Statement of the World Congress of Gastroenterology on Biological Therapy
33 for IBD with the European Crohn's and Colitis Organisation: pregnancy and
34 pediatrics. *The American journal of gastroenterology* 2011;106(2):214-23; quiz 24.
35
- 36 19. Ng SW, Mahadevan U. Management of inflammatory bowel disease in pregnancy. *Expert*
37 *review of clinical immunology* 2013;9(2):161-74.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 20. Ostensen M, Forger F. Management of RA medications in pregnant patients. *Nature*
4
5 *reviews. Rheumatology* 2009;5(7):382-90.
6
7 21. Syme MR, Paxton JW, Keelan JA. Drug transfer and metabolism by the human placenta.
8
9 *Clinical pharmacokinetics* 2004;43(8):487-514.
10
11 22. Buckley LM, Bullaboy CA, Leichtman L, Marquez M. Multiple congenital anomalies
12 associated with weekly low-dose methotrexate treatment of the mother. *Arthritis and*
13 *rheumatism* 1997;40(5):971-3.
14
15 23. Lloyd ME, Carr M, McElhatton P, Hall GM, Hughes RA. The effects of methotrexate on
16 pregnancy, fertility and lactation. *QJM : monthly journal of the Association of*
17 *Physicians* 1999;92(10):551-63.
18
19 24. Brent RL. Teratogen update: reproductive risks of leflunomide (Arava); a pyrimidine
20 synthesis inhibitor: counseling women taking leflunomide before or during pregnancy
21 and men taking leflunomide who are contemplating fathering a child. *Teratology*
22 2001;63(2):106-12.
23
24 25. Chakravarty EF, Sanchez-Yamamoto D, Bush TM. The use of disease modifying
25 antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a
26 survey of practice patterns and pregnancy outcomes. *The Journal of rheumatology*
27 2003;30(2):241-6.
28
29 26. Langen ES, Chakravarty EF, Liaquat M, El-Sayed YY, Druzin ML. High Rate of Preterm
30 Birth in Pregnancies Complicated by Rheumatoid Arthritis. *American journal of*
31 *perinatology* 2013.
32
33 27. Hameen-Anttila K, Jyrkka J, Enlund H, Nordeng H, Lupattelli A, Kokki E. Medicines
34 information needs during pregnancy: a multinational comparison. *BMJ open*
35 2013;3(4).
36
37 28. Peters SL, Lind JN, Humphrey JR, Friedman JM, Honein MA, Tassinari MS, et al. Safe
38 lists for medications in pregnancy: inadequate evidence base and inconsistent
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 guidance from Web-based information, 2011. *Pharmacoepidemiology and drug*
4
5 *safety* 2013;22(3):324-8.
6

7 29. Toomey D, Waldron B. Family planning and inflammatory bowel disease: the patient and
8
9 the practitioner. *Family practice* 2013;30(1):64-8.
10

11 30. van der Woude CJ, Kolacek S, Dotan I, Oresland T, Vermeire S, Munkholm P, et al.
12
13 European evidenced-based consensus on reproduction in inflammatory bowel
14
15 disease. *Journal of Crohn's & colitis* 2010;4(5):493-510.
16

17 31. Finer LB, Henshaw SK. Disparities in rates of unintended pregnancy in the United States,
18
19 1994 and 2001. *Perspectives on sexual and reproductive health* 2006;38(2):90-6.
20
21

22 32. Panchal S, Khare M, Moorthy A, Samanta A. Catch me if you can: a national survey of
23
24 rheumatologists and obstetricians on the use of DMARDs during pregnancy.
25
26 *Rheumatology international* 2013;33(2):347-53.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Figure 1.** Frequency of physician-initiated discussions regarding FPP issues with female
4 patients and their GPs or gynaecologists (survey Phase 2 data shown in B and C)

5
6
7 *Abbreviations:* Ga = gastroenterologist; Rh = rheumatologist. * $p < 0.05$ compared to Phase 1
8
9 (two-sided z-test with significance level 0.05)

10
11
12
13 **Figure 2.** Patient reported (patient survey) topics of discussion with specialist physicians,
14 the frequency of patient-initiated FPP discussion and the importance of FPP issues stratified
15 by patient age (data from survey Phase 2 shown in C)


16
17
18
19
20
21
22 **Figure 3.** Patient preference for frequency of discussions relating to FPP issues and
23 identification of issues that prevented discussion (data from patient survey Phase 2 shown)

24
25
26
27
28 **Figure 4.** Patient preference for choice of healthcare provider for discussions of their
29 condition and FPP issues, and their preferred source of additional information (outside
30 doctors' office/clinic/surgery) relating to both their condition and FPP issues (data from
31 patient survey Phase 2 shown)


32
33
34
35
36
37
38 **Figure 5.** FPP-related considerations for practicing physicians treating female patients of
39 child-bearing age who live with chronic inflammatory disease: key messages from the survey
40 of current clinical practice and patient perceptions.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

A) Proportion of physicians who report having discussed family planning topics with female patients of child-bearing age (last 3 patients were considered)



B) To what extent did you discuss these questions, issues...with the patient's GP? [see Question 20 of the Physician Survey, Appendix 1]



C) To what extent did you discuss these questions, issues...with the patient's gynaecologist? [see Question 21 of the Physician Survey, Appendix 1]






Figure 1. Frequency of physician-initiated discussions regarding FPP issues with female patients and their GPs or gynaecologists (survey Phase 2 data shown in B and C) Abbreviations: Ga = gastroenterologist; Rh = rheumatologist. *p<0.05 compared to Phase 1 (two-sided z-test with significance level 0.05)
217x306mm (300 x 300 DPI)

A) Topics discussed during any of the last three medical appointments



B) Have family planning concerns ever been discussed?



C) Are family planning issues of concern?





Figure 2. Patient reported (patient survey) topics of discussion with specialist physicians, the frequency of patient-initiated FPP discussion and the importance of FPP issues stratified by patient age (data from survey Phase 2 shown in C).
180x128mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

A) How often would you like the topic of family planning to be brought up during your medical appointments?



B) Issues that prevented a discussion




Figure 3. Patient preference for frequency of discussions relating to FPP issues and identification of issues that prevented discussion (data from patient survey Phase 2 shown).
180x126mm (300 x 300 DPI)

View only




Figure 4. Patient preference for choice of healthcare provider for discussions of their condition and FPP issues, and their preferred source of additional information (outside doctors' office/clinic/surgery) relating to both their condition and FPP issues (data from patient survey Phase 2 shown).
180x138mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 5. FPP-related considerations for practicing physicians treating female patients of child-bearing age who live with chronic inflammatory disease: key messages from the survey of current clinical practice and patient perceptions.
145x117mm (300 x 300 DPI)

view only

Appendix 1

Physician Survey Questionnaire

Overview – survey flow

1. Participant profiling and screening
2. Implicit measurement of impact FPP
3. Communication testing
4. Explicit measurement of FPP related conversations

Thank you for your interest in our study. Before we begin, we would like to assure you that we act in accordance with the ESOMAR, EphMRA, ABPI, MRS and BHBIA codes of conduct regarding anonymity and confidentiality.

Any information you disclose will be treated in the strictest confidence and the results are pooled so none of the answers are attributable to individual respondents.

First we would like to ask you a few qualifying questions. This will take less than 1 minute. The questionnaire takes some 20 minutes to complete and covers the domain of Rheumatoid Arthritis/Crohn's Disease.

The market research is being conducted on behalf of a pharmaceutical company. The market research study itself is strictly non-promotional. The company commissioning this research has no access whatsoever to information regarding respondents.

If you have any problems or questions filling out this questionnaire, please feel free to contact us at support@leadphysician.com.

- I hereby agree to proceed with the questionnaire on this basis. **STOP if not selected**

The participant should agree to treat with the utmost confidentiality all data and information to which he is made privy in light of and/or as a result of his participation in this study.

The participant expressly guarantees that he will not divulge said information or data, nor will third parties be granted access. He will not publish or reproduce the information, nor will he exploit it in any other way.

Only public information or information that the participant may also obtain via other legitimate means than through participation in this study are not subject to this obligation of confidentiality.

This obligation is irrevocable and remains in effect as long as the information is to be considered confidential and has, therefore, not been made public by the authorized party or parties.

- Yes, I expressly and unconditionally accept the above obligation of confidentiality.
STOP if not selected

ADVERSE EVENT REPORTING: We have been asked to provide our client with details of adverse events divulged during the course of this market research. Although this is an online survey and the information you provide will of course be treated in confidence, we are still under an obligation to report any information on adverse events in specific patients, even if you have already reported said event to the company or the regulatory authorities. In this case you will be contacted with a request to waive the confidentiality provided under the market research codes of conduct specifically for this particular adverse event. All other information you provide during the course of the survey will remain confidential.

- I hereby confirm to have been informed that the organiser of the survey is under the obligation to collect and report all information on adverse events linked to the client's product as recorded by me during the course of this research. **STOP if not selected**

[Parameters to be recorded from panel database:

- Age
- Gender
- Region
- No Clinical investigation or pharma/biotech manufacturer (not in US)]

PARTICIPANT PROFILING AND SCREENING

1. What is your primary specialty?

Question type: Single response

- | | |
|---|---------------------|
| <input type="checkbox"/> Gastroenterology (US only) | =GASTROENTEROLOGIST |
| <input type="checkbox"/> Rheumatology | = RHEUMATOLOGIST |
| <input type="checkbox"/> Internal medicine specialized in rheumatology (Germany only) | = RHEUMATOLOGIST |
| <input type="checkbox"/> Internal medicine not specialized in rheumatology (Germany only) | STOP |
| <input type="checkbox"/> Other specialty | STOP |

[Gastroenterologists get questions personalized to Crohn's Disease, Rheumatologists to Rheumatoid Arthritis.]

2. How long have you been IN PRACTICE since qualifying as a specialist?

[Question type: Open comment - numeric

Max score allowed: 50 ("Years" - next to box)]

[If < 3 or > 30 => STOP]

3. What percent of your working time is dedicated to treating patients?

1
2
3 [Question type: Open comment - numeric

4
5 0 to 100%]

6
7
8
9 % is dedicated to treating patients [STOP if less than 50%]

10
11
12
13
14
15 **4. In an average month, approximately how many different patients do you see for all disorders**
16 **and conditions and for whom you are personally involved in making treatment decisions? Please**
17 **count each patient once, not the number of visits.**

18
19 [Question type: Open comment - numeric

20
21 Max score allowed: 1000]

22
23 [STOP if <20]

24
25

26
27
28
29
30
31 **5. In an average month, approximately how many different patients do you see for Rheumatoid**
32 **Arthritis (for Rheumatologists)/ Crohn's Disease (for Gastroenterologists) and for whom you are**
33 **personally involved in making treatment decisions? Please count each patient once, not the**
34 **number of visits.**

35
36 [Question type: Open comment - numeric

37
38 Max score allowed: number at S4

39
40 Number needs to be lower or equal than in previous question.]

41
42 [STOP if < 20 RA patients or < 8 CD patients]

43
44

1
2
3 **6. In an average month, approximately how many different patients with Rheumatoid Arthritis**
4 **(for Rheumatologists)/ Crohn's Disease (for Gastroenterologists) do you see that are on biologic**
5 **treatment?**
6

7 *[Question type: Open comment - numeric]*

8
9 *Max score allowed: Number in S5*

10
11 *Number needs to be lower or equal than in previous question]*

12
13 *[STOP if < 10 RA patients or < 2 CD patients]*

14
15
16

17
18
19 **7. What type of practice do you have? (tick only one)**

20
21 *[Question type: Single response]*

- 22
23 Office only *[STOP in France]*
24 Hospital only
25 Office and hospital *[(don't show in Germany)]*
26
27

28
29 **8. What is the size of hospital where you carry out your regular practice?**

30
31 *[Question type: Single response]*

32
33 *[Show only if 'hospital' or 'office and hospital' was selected in q0]*

- 34 More than 700 beds
35 400 to 700 beds
36 Less than 400 beds
37

38
39 **9. Have you taken part in a market research study in the area of Rheumatoid Arthritis (for**
40 **Rheumatologists)/ Crohn's Disease (for Gastroenterologists) in the last month?**

41 *[Question type: Single response]*

- 42 Yes **[STOP]**
43 No
44
45

46
47 **10. What percentage of your Rheumatoid Arthritis/Crohn's Disease patient base can be attributed**
48 **to the following categories?**

49
50 *[Question type: Open comment - numeric]*

51
52 *Should add up to 100%*

53

Male younger than 45 years old	%
Male 45 years or older	%
Female younger than 45 years old	%
Female 45 years or older	%

54
55
56
57
58
59
60

IMPLICIT MEASUREMENT OF IMPACT FPP

In the following questions we would like to talk about the topics you discussed with your moderate to severe Rheumatoid Arthritis/Crohn’s Disease patients.

Obviously, most of the conversations are about clinical topics, but from now on we would like you to think about **non clinical nor treatment related topics**.

11. Please think back about your last 6 [3: IF Q10_1 OR Q10_2=0] male patients with moderate to severe Rheumatoid Arthritis/Crohn’s Disease that were initiated on treatment by you. Which topics did you discuss with these patients?

Please bear in mind to mention non clinical and non-treatment related topics.

[Question type: Open comment – text]

	Last 3 patients younger than 45 years old [only show if Q10 “Male younger than 45 years old” > 0]	Last 3 patients of 45 years or older [only show if Q10 “Male 45 years or older” > 0]
Male patient 1		
Male patient 2		
Male patient 3		

12. Please think back about your last 6 [3: IF Q10_3 OR Q10_4=0] female patients with moderate to severe Rheumatoid Arthritis/Crohn’s Disease that were initiated on treatment by you. Which topics did you discuss with these patients?

Please bear in mind to mention non clinical and non-treatment related topics.

[Question type: Open comment – text]

	Last 3 patients younger than 45 years old [only show if Q10 “Female younger than 45 years old” > 0]	Last 3 patients of 45 years or older [only show if Q10 “Female 45 years or older” > 0]
Female patient 1		
Female patient 2		
Female patient 3		

1
2
3 **13. Please think back about your last male patients with moderate to severe Rheumatoid**
4 **Arthritis/Crohn's Disease that were initiated on treatment by you.**

5
6 **Other than disease related topics, which of the following topics did you discuss with these**
7 **patients?.**

8
9
10 *[Question type: Multiple response]*

11 *[Randomisation: Yes]*

12
13
14
15 LAST 3 MALE PATIENTS YOUNGER THAN 45 YEARS *[only show if Q10 "Male younger than 45 years*
16 *old" > 0]*

- 17
18
19
20
21
22
23
24
25
26
27
28
29
30
- Ability to gain/maintain employment
 - Emotional wellbeing of the patient
 - Social life of the patient
 - Conception / having children
 - Sex life
 - Sports activities
 - Leisure / holiday
 - Independent living of the patient
 - Family life
 - Finances
 - Other (please specify)
 - None of the above

31
32 LAST 3 MALE PATIENTS OF 45 YEARS OR OLDER *[only show if Q10 "Male 45 years or older" > 0]*

- 33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
- Ability to gain/maintain employment
 - Emotional wellbeing of the patient
 - Social life of the patient
 - Conception / having children
 - Sex life
 - Sports activities
 - Leisure / holiday
 - Independent living of the patient
 - Family life
 - Finances
 - Other (please specify)
 - None of the above

48
49 **14. Below, we have listed the topics you discussed with your last male patients with moderate to**
50 **severe Rheumatoid Arthritis/Crohn's Disease.**

51
52 Please select the 5 topics you spent most time on, and rank them by attributing a score between 1
53 and 5, where 1 indicates the topic you spent most time on.

54
55 *[PN: Show text before each part of question and adjust number of topics selected when less than 5]*

56
57 *[Question type: ranking (top 5)]*

1
2
3 *Randomisation: Yes]*
4 *[Filter: only show options selected in Q13]*
5
6

7 LAST 3 MALE PATIENTS YOUNGER THAN 45 YEARS (max 5)
8

- 9 Ability to gain/maintain employment
- 10 Emotional wellbeing of the patient
- 11 Social life of the patient
- 12 Conception / having children
- 13 Sex life
- 14 Sports activities
- 15 Leisure / holiday
- 16 Independent living of the patient
- 17 Family life
- 18 Finances
- 19 Other (please specify)

20
21 LAST 3 MALE PATIENTS OF 45 YEARS OR OLDER (max 5)
22

- 23 Ability to gain/maintain employment
- 24 Emotional wellbeing of the patient
- 25 Social life of the patient
- 26 Conception / having children
- 27 Sex life
- 28 Sports activities
- 29 Leisure / holiday
- 30 Independent living of the patient
- 31 Family life
- 32 Finances
- 33 Other (please specify)

34
35
36 **15. Please think of your last male patient with whom you discussed conception / having children.**
37

38 **Who initiated this discussion on conception / having children?**
39

40 *[Question type: Single response]*
41

42 *[Filter: only show if "Conception / having children" is selected in Q0]*
43

- 44 I initiated this discussion
- 45 The patient initiated this discussion
- 46 I don't remember who initiated this discussion
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

1
2
3 **16. Please think back about your last female patients with moderate to severe Rheumatoid**
4 **Arthritis/Crohn's Disease that were initiated on treatment by you.**

5
6 **Other than disease related topics, which of the following topics did you discuss with these**
7 **patients?**

8
9
10 *[Question type: Multiple response]*

11 *[Randomisation: Yes]*

12
13
14
15 LAST 3 FEMALE PATIENTS YOUNGER THAN 45 YEARS *[only show if Q10 "Female younger than 45*
16 *years old" > 0]*

- 17
18 Ability to gain/maintain employment
19 Emotional wellbeing of the patient
20 Social life of the patient
21 Conception / having children
22 Sex life
23 Sports activities
24 Leisure / holiday
25 Independent living of the patient
26 Family life
27 Finances
28 Other (please specify)
29 None of the above

30
31 LAST 3 FEMALE PATIENTS OF 45 YEARS OR OLDER *[only show if Q10 "Female 45 years or older" > 0]*

- 32
33 Ability to gain/maintain employment
34 Emotional wellbeing of the patient
35 Social life of the patient
36 Conception / having children
37 Sex life
38 Sports activities
39 Leisure / holiday
40 Independent living of the patient
41 Family life
42 Finances
43 Other (please specify)
44 None of the above

45
46
47
48 **17. Below, we have listed the topics you discussed with your last female patients with moderate**
49 **to severe Rheumatoid Arthritis/Crohn's Disease.**

50
51
52 **Please select the 5 topics you spent most time on, and rank them by attributing a score between 1**
53 **and 5, where 1 indicates the topic you spent most time on.**

54
55 *[PN: Show text before each part of question and adjust number of topics selected when less than 5]*

56
57 *[Question type: ranking (top 5)]*

1
2
3 *[Randomisation: Yes]*

4 *[Filter: only show options selected in Q16]*

5
6
7 LAST 3 FEMALE PATIENTS YOUNGER THAN 45 YEARS (max 5)

- 8
9 Ability to gain/maintain employment
- 10 Emotional wellbeing of the patient
- 11 Social life of the patient
- 12 Conception / having children
- 13 Sex life
- 14 Sports activities
- 15 Leisure / holiday
- 16 Independent living of the patient
- 17 Family life
- 18 Finances
- 19 Other (please specify)

20
21 LAST 3 PATIENTS OF 45 YEARS OR OLDER (max 5)

- 22
23 Ability to gain/maintain employment
- 24 Emotional wellbeing of the patient
- 25 Social life of the patient
- 26 Conception / having children
- 27 Sex life
- 28 Sports activities
- 29 Leisure / holiday
- 30 Independent living of the patient
- 31 Family life
- 32 Finances
- 33 Other (please specify)

34
35 **18. Please think of your last female patient with whom you discussed conception / having**

36 **children.**

37
38 **Who initiated this discussion on conception / having children?**

39
40 *[Question type: Single response]*

41
42 *[Filter: only show if "Conception / having children" is selected in Q6]*

- 43
44 I initiated this discussion
- 45 The patient initiated this discussion
- 46 I don't remember who initiated this discussion
- 47
48
49
50
51
52
53
54
55
56
57
58
59
60

QUESTIONS REGARDING FPP MANAGEMENT

In the next chapter, we would like to ask you some questions regarding the Family Planning and Pregnancy management of your patients with moderate to severe Rheumatoid Arthritis/Crohn's Disease.

19. How often do you consult the following channel(s) in order to look for extra information regarding Family Planning and Pregnancy issues?

[Question type: Single response]

[Randomise options]

	Always	Very often	Sometimes	Rarely	Never
Congresses/meetings	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Medical Science Liaison (MSL)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Sales representative	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Industry-sponsored symposia or meetings	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Company websites with disease management education	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Social media (e.g. Facebook, LinkedIn, Twitter) for your profession (please specify):	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Other healthcare professionals (peers)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Expert opinion blogs (please specify):	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Physician communities (please specify):	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
KOLs (Key Opinion Leaders)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Online consultation	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Other (please specify):	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

The family planning and/or pregnancy related issues, questions... your patients with moderate to severe Rheumatoid Arthritis/Crohn's Disease could have, might also be relevant for their other treating physicians.

[Filter: only show if "Conception / having children" is selected in Q0 or Q0]

20. To what extent do you discuss these questions, issues... with the patient's GP?

[Question type: Single response]

[Filter: only show if "Conception / having children" is selected in Q0 or Q0]

1 Never discuss with patient's GP	2	3	4	5 Always discuss with patient's GP
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

21. To what extent do you discuss these questions, issues... with the patient's gynaecologist?

[Question type: Single response]

[Filter: only show if "Conception / having children" is selected in Q0]

1 Never discuss with patient's gynaecologist	2	3	4	5 Always discuss with patient's gynaecologist
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Appendix 2**Patient Survey Questionnaire**

1. Please specify the country where you live:

- United States
- United Kingdom
- France
- Italy
- Germany
- Spain
- Other (OUT)

2. Please specify your gender:

- Male (OUT)
- Female

3. Please specify your age:

- Under 20 years (OUT)
- 20-24 years
- 25-29 years
- 30-34 years
- 35-39 years
- 40-45 years
- Over 45 years (OUT)

1
2
3 4. How many children have you given birth to?
4
5

- 6 • None
- 7 • One
- 8 • Two
- 9 • Three
- 10 • Four
- 11 • Five or more

12
13
14
15
16
17
18 5. Do you have an immunological condition? If so, which one? (If you have more
19 than one of these conditions, tick the one that is most prominent)
20

- 21 • Rheumatoid arthritis
- 22 • Systemic lupus
- 23 • Crohn's disease
- 24 • Ulcerative colitis
- 25 • Axial spondyloarthritis
- 26 • Psoriatic arthritis
- 27 • None (OUT)
- 28 • Other (OUT)

29
30
31
32
33
34
35
36
37
38
39 6. Are you currently taking any medication for your condition?
40

- 41 • Yes
 - 42 • No
- 43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Next, we would like to ask you a few questions around your visits to your doctor.
4

5 7. Which doctor(s) did you visit during the last two years for your condition? (please
6 tick all that apply)
7

- 8 • GP
- 9 • Gynaecologist
- 10 • Rheumatologist
- 11 • Gastroenterologist
- 12 • Immunologist
- 13 • Dermatologist
- 14 • Other

15
16
17
18
19
20
21
22 8. During any of your last three medical appointments, did you discuss any of the
23 following topics in relation to your condition? (please tick all that apply)
24

- 25 • Employment
- 26 • Emotional wellbeing
- 27 • Social life
- 28 • Having children/pregnancy [if ticked, option 9 of Q11 was hidden]
- 29 • Sex life
- 30 • Sports activities
- 31 • Leisure/holiday
- 32 • Independent living
- 33 • Family life
- 34 • Finances

1
2
3 Finally, we would like to ask you about family planning (having children), and how you
4
5 discuss this during your medical appointment.
6

7 9. Are you considering having a child/another child?

- 8 • Yes
- 9 • No

10
11
12 10. Do you consider your condition a point of concern for family planning (i.e. for
13 your plans of having another child)?

- 14 • Yes
- 15 • No

16
17
18 11. Have you ever discussed your concerns around your condition and family
19 planning with a healthcare professional (specialist, GP or nurse)? (please tick all
20 that apply)

- 21 • Yes, with my GP
- 22 • Yes, with my gynaecologist
- 23 • Yes, with my paediatrician
- 24 • Yes, with my rheumatologist
- 25 • Yes, with my gastroenterologist
- 26 • Yes, with my immunologist
- 27 • Yes, with my dermatologist
- 28 • Yes, with a nurse
- 29 • No, I haven't discussed this [this option will not appear if FPP is ticked in
30 Q8; if ticked only Q16-23 subsequently shown]
- 31 • Other

1
2
3 12. When was the last time you discussed your concerns around your condition and
4
5 family planning with a healthcare professional (specialist, GP or nurse)?
6

- 7 • Less than six months ago
- 8
- 9 • Between six months and two years ago
- 10
- 11 • More than two years ago
- 12
- 13 • Don't remember
- 14

15
16 13. Over the last five years, how frequently did you have a discussion on your
17
18 concerns around your condition and family planning with a healthcare
19
20 professional (specialist, GP or nurse)?
21

- 22 • Every visit
- 23
- 24 • Most visits
- 25
- 26 • Occasionally, during some visits
- 27
- 28 • Just once
- 29
- 30 • Never
- 31
- 32 • Don't remember
- 33
- 34

35 14. Who initiated the last discussion around your condition and family planning?
36

- 37 • I did
- 38
- 39 • The doctor or nurse did
- 40
- 41 • Don't remember
- 42

43 15. To what extent did that discussion settle concerns? (please rate on a scale from
44
45 0 to 10 where 0 = no, the discussion didn't settle my concerns at all, and 10 =
46
47 yes, the discussion completely settle my concerns)
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 16. Do you intend to make family planning a discussion point during your next
4
5 medical appointment? (omitted in UK)
6

- 7 • Yes, definitely
- 8
- 9 • Yes, probably
- 10
- 11 • Maybe
- 12
- 13 • No, probably not
- 14
- 15 • No, definitely not
- 16

17
18 *Additional questions for Phase 2 questionnaire*
19

20 17. Which of the issues listed below prevented you from discussing your concerns
21
22 around your condition and family planning during your medical appointments?
23
24 (maximum 2)
25

- 26 • Not enough time on behalf of my doctor or other healthcare professional
- 27
- 28 • I forgot to bring up my concerns
- 29
- 30 • I feel the healthcare professionals I am seeing are unable to help me here
- 31
- 32 • The healthcare professionals I am seeing are reluctant to enter into this
- 33 discussion
- 34
- 35 • I am very worried that bringing up my concerns will trigger a change in
- 36 my medication, which will make symptoms worse
- 37
- 38 • Other
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

1
2
3 18. What type of healthcare professional (specialist, GP or nurse) are you primarily
4
5 seeing in relation to your condition? (only 1 allowed)
6

- 7 • GP
- 8
- 9 • Gynaecologist
- 10
- 11 • Paediatrician
- 12
- 13 • Rheumatologist
- 14
- 15 • Gastroenterologist
- 16
- 17 • Immunologist
- 18
- 19 • Dermatologist
- 20
- 21 • Nurse
- 22
- 23 • Other
- 24
- 25

26
27 19. What type of healthcare professional (specialist, GP or nurse) are you primarily
28
29 seeing in relation to family planning and pregnancy? (only 1 allowed)
30

- 31 • GP
- 32
- 33 • Gynaecologist
- 34
- 35 • Paediatrician
- 36
- 37 • Rheumatologist
- 38
- 39 • Gastroenterologist
- 40
- 41 • Immunologist
- 42
- 43 • Dermatologist
- 44
- 45 • Nurse
- 46
- 47 • Other
- 48
- 49

50 20. If you discussed your concerns around family planning and your condition with
51
52 several healthcare professionals (specialists, GP or nurse), how consistent would
53
54 you say the answers were? (please rate on a scale from 0 to 10 where 0 = the
55
56 answers were not consistent at all, and 10 = the answers were very consistent)
57
58
59
60

1
2
3 21. Which channels are you using to find information about family planning as
4
5 impacted by your condition? (please tick all that apply)
6

- 7 • Family and friends
- 8
- 9 • Fellow patients
- 10
- 11 • Other pregnant women and mothers
- 12
- 13 • Twitter
- 14
- 15 • Facebook
- 16
- 17 • Specific condition related websites
- 18
- 19 • Specific pregnancy related websites
- 20
- 21 • Health blogs
- 22
- 23 • Specific condition related forums (online)
- 24
- 25 • Specific pregnancy related forums (online)
- 26
- 27 • TV
- 28
- 29 • Magazines or e-magazines
- 30
- 31 • Books or e-books
- 32
- 33 • DVDs/CDs
- 34
- 35 • Patient organisations
- 36
- 37 • Radio
- 38
- 39 • Health and wellness clubs
- 40
- 41 • Religious groups
- 42
- 43 • Condition related groups (not online)
- 44
- 45 • Other
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

1
2
3 22. Which channels are you using to engage (comment, discuss, post, share, like) in
4 discussions around family planning as impacted by your condition? (please tick all
5 that apply)
6
7
8

- 9 • Family and friends
- 10
- 11 • Fellow patients
- 12
- 13 • Other pregnant women and mothers
- 14
- 15 • Twitter
- 16
- 17 • Facebook
- 18
- 19 • Specific condition related websites
- 20
- 21 • Specific pregnancy related websites
- 22
- 23 • Health blogs
- 24
- 25 • Specific condition related forums (online)
- 26
- 27 • Specific pregnancy related forums (online)
- 28
- 29 • Patient organisations
- 30
- 31 • Health and wellness clubs
- 32
- 33 • Religious groups
- 34
- 35 • Condition related groups (not online)
- 36
- 37 • Other
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

1
2
3 23. What is in your opinion the best way to bring up the topic of family planning and
4
5 your condition during a medical appointment?
6

- 7
- 8 • I would like a healthcare professional (specialist, GP or nurse) to initiate
9 the discussion
10
 - 11 • I would like a healthcare professional (specialist, GP or nurse) to provide
12 me with some informational materials about family planning and my
13 condition
14
 - 15 • I would prefer to initiate the discussion myself
16
 - 17 • I would prefer not to have such discussion [GO TO END]
18
 - 19 • Other [GO TO END]
20
- 21
22
23

24 24. How often would you like the topic of family planning be brought up during your
25
26 medical appointments?
27

- 28
- 29 • Once is enough
30
 - 31 • At every visit
32
 - 33 • When changing my medication
34
 - 35 • When taking decisions that could have an impact on my family planning
36
 - 37 • Regularly, at least once a year
38
 - 39 • Every time when my condition is stable enough to become pregnant
40
- 41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60